[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 991
1. Ferreira AC, Brum S, Carvalho D, Pataca I, Carvalho F, Santos MC, Santos JR: Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia. Hemodial Int; 2010 Jan;14(1):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia.
  • Renal failure due to leukemic infiltration of kidney in chronic lymphocytic leukemia is an extremely rare condition.
  • The authors report a case of a 59-year-old white female, with a past medical history of chronic lymphocytic leukemia (CLL) with 2 years of evolution without medical therapy, admitted with nonoliguric acute renal failure needing dialysis.
  • Renal biopsy showed extensive small lymphocytes' infiltration in the cortical interstitium by CLL cells.
  • Although renal failure due to leukemic infiltration has been described in many cases of acute leukemia, only 11 cases of renal failure due to CLL cells' infiltration have been described in the literature.
  • [MeSH-major] Kidney / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758305.001).
  • [ISSN] 1542-4758
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


2. Openshaw H, Ressler JA, Snyder DS: Lumbar puncture and subdural hygroma and hematomas in hematopoietic cell transplant patients. Bone Marrow Transplant; 2008 May;41(9):791-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbar puncture and subdural hygroma and hematomas in hematopoietic cell transplant patients.
  • We reviewed records of hematopoietic cell transplantation (HCT) patients seen over the past 10 years who had head scan documentation of subdural fluid collections.
  • Acute lymphocytic leukemia was the diagnosis in five of these eight; whereas, either acute myelogenous leukemia or myelodysplasia was the diagnosis in seven of the nine patients without lumbar puncture.
  • [MeSH-major] Hematologic Neoplasms / therapy. Hematoma, Subdural, Spinal. Hematopoietic Stem Cell Transplantation. Spinal Puncture / adverse effects. Subdural Effusion

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246118.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica; 2007 Aug;92(8):1059-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: In the present paper we report that SAP, an intracytoplasmic molecule that is involved in cell signaling, is an immunohistologic marker for germinal center T cells in paraffin-embedded tissue.
  • We document its expression, and also that of PD-1 (another recently described marker of germinal center T cells to which a new antibody has been raised), in normal and neoplastic lymphoid tissue to evaluate the suggestion that helper T cells within the germinal centers of human lymphoid tissue are the cell of origin of angioimmunoblastic T-cell lymphoma (AITL), and to assess the diagnostic value of these two markers.
  • DESIGN AND METHODS: Expression of SAP and PD-1 was investigated by immunohistochemistry in paraffin-embedded tissue sections and in cell lines.
  • Western blotting was performed on cell lines, and antibody specificity was confirmed by immunostaining of transfected cells.
  • SAP was also expressed on many cases (15/21) of acute T lymphoblastic leukemia, in keeping with its presence in cortical thymocytes.
  • However, PD-1 and SAP were also found in a minority of cases of peripheral T-cell lymphoma other than AITL, in contrast to a report that the former marker is specific for AITL.
  • They may also prove of value in the diagnosis of this disease since a negative reaction was rarely observed in this disorder.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antigens, CD / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Intracellular Signaling Peptides and Proteins / analysis. Lymphoma, T-Cell / pathology. Neoplasm Proteins / analysis. T-Lymphocytes / chemistry
  • [MeSH-minor] Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphocytes, Tumor-Infiltrating / chemistry. Lymphocytes, Tumor-Infiltrating / pathology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / pathology. Palatine Tonsil / pathology. Programmed Cell Death 1 Receptor. Spleen / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / SH2D1A protein, human
  •  go-up   go-down


Advertisement
4. Char DH, Shiel MJ: Orbital meningioma after cranial radiation for acute lymphocytic leukemia. Orbit; 2008;27(4):321-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital meningioma after cranial radiation for acute lymphocytic leukemia.
  • PURPOSE: To describe the ophthalmic findings of cranial radiation-induced orbital meningioma after acute lymphocytic leukemia therapy.
  • RESULTS: We describe two patients recently evaluated with orbital meningiomas many years after cranial radiation for acute lymphocytic leukemia.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716974.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Wang ZY, Chen QS: [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr;13(2):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial].
  • One of the important approaches for further prolonging remission duration and eradicating minimal residual disease in acute leukemia is immunotherapy.
  • Four kinds of immunotherapy for acute leukemia are under investigation:.
  • (1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates.
  • Other Mabs under preclinical and clinical trials include anti-IL-2 receptor Mab for the treatment of acute T lymphocytic leukemia, anti-220 kD Mab-6G7 for acute leukemias, recombinant immune toxin BL22 (anti-CD22) for hairy cell leukemia and Mabs labeled with radio-isotopes for different types of acute leukemias;.
  • (2) adoptive cellular immunotherapy using cytokine-induced killer cell, alloreactive NK cells, allogeneic or autologous leukemic-specific CD8(+) cytotoxic T lymphocytes, and other immune effector cells;.
  • (4) leukemia vaccines of several different formulations including antigen-specific, leukemia cell-based, leukemia antigen-pulsed dendritic cell (DC) and leukemia-derived DC vaccines, the latter two formulations are more attractive.
  • In conclusion, up to now, the most effective example of immunotherapy in acute leukemia is provided by the administration of Mabs, and the majority of other approaches in immunotherapy for acute leukemia although promising, need further studies.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854271.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines
  •  go-up   go-down


6. Robinson KE, Livesay KL, Campbell LK, Scaduto M, Cannistraci CJ, Anderson AW, Whitlock JA, Compas BE: Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses. Pediatr Blood Cancer; 2010 Apr;54(4):585-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses.
  • PROCEDURE: This study used functional neuroimaging techniques to examine working memory and executive functioning deficits of survivors of childhood acute lymphocytic leukemia (ALL), as compared to age- and gender-matched healthy controls.

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2002 Jun;125(Pt 6):1275-82 [12023316.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):88-92 [12461791.001]
  • [Cites] Biol Psychiatry. 2003 Mar 1;53(5):376-84 [12614990.001]
  • [Cites] Dev Psychol. 2003 Jul;39(4):761-76 [12859128.001]
  • [Cites] Hum Brain Mapp. 2003 Oct;20(2):51-8 [14505331.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1021:296-309 [15251900.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2082-90 [15341983.001]
  • [Cites] Child Dev. 2004 Sep-Oct;75(5):1357-72 [15369519.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):61-9 [15588597.001]
  • [Cites] Hum Brain Mapp. 2005 May;25(1):46-59 [15846822.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):357-63 [16179658.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] Hum Brain Mapp. 2006 Jan;27(1):28-36 [16001441.001]
  • [Cites] Hum Brain Mapp. 2006 May;27(5):392-401 [16596654.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1094:226-34 [17347354.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):65-73 [16628558.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • (PMID = 19953649.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068485-13S4; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / CA068485; United States / NCI NIH HHS / CA / P30 CA068485-13S4
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS183910; NLM/ PMC2901833
  •  go-up   go-down


7. Zeng Y, Ni X, Meng WT, Wen Q, Jia YQ: [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;40(6):1038-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells].
  • OBJECTIVE: To test the effect of Artesunate (ART) on the proliferation of Raji cells, Jurkat cells and acute lymphoblastic leukemia (ALL) primary cells; to determine the synergistic antiproliferation effect between ART and Vincristine (VCR) or Cytarabine(Ara-C) on Raji and Jurkat cells; and to explore the mechanism of ART induced apoptosis of tumor cells in vitro.
  • CONCLUSION: ART alone or combined with chemotherapy drugs could inhibit the proliferation of B/T lymphocytic tumor cell lines as well ALL primary cells in vitro, probably through the mechanism of apoptosis, which suggest that ART is likely to be a potential drug in the treatment of leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Artemisinins / pharmacology. Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Blood-Brain Barrier / drug effects. Cell Line, Tumor. Cytarabine / pharmacology. Drug Synergism. Humans. Jurkat Cells

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067115.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 04079A1RDZ / Cytarabine; 60W3249T9M / artesunate
  •  go-up   go-down


8. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.
  • We discuss the possibility of a link between BWS and leukaemia via one of the few known negative regulator of hematopoiesis, the transforming growth factor beta pathway, depending upon the up-regulation of CDKN1C.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


9. Romano S, Di Pace A, Sorrentino A, Bisogni R, Sivero L, Romano MF: FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem; 2010 Nov 1;10(9):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These pathways are related to T-cell activation and growth.
  • The signaling pathway involving calcineurin and nuclear factors of activated T-lymphocytes is also involved in the pathogenesis of different cancer types and in tumor metastasis, providing a rationale for use of FK506 in anticancer therapy.
  • Recent studies have focused on FKBPs in apoptosis regulation: Targeting of FKBP12 promotes apoptosis in chronic lymphocytic leukemia, FKBP38 knockdown sensitizes hepatoma cells to apoptosis, and FKBP51 silencing overcomes resistance to apoptosis in acute lymphoblastic leukemia, prostate cancer, melanoma, and glioma.
  • Interestingly, derivatives of FK506 that have the same FKBP12-binding properties as FK506 but lack functional immunosuppressant activity, exert the same apoptotic effect as FK506 in chronic lymphocytic leukemia.These findings suggest that a direct FKBP inhibition represents a further mechanism of immunosuppressants.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21182472.001).
  • [ISSN] 1875-5992
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; EC 5.2.1.- / Tacrolimus Binding Proteins; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


10. Abolfazl M, Fatemeh I, Hamid A, Mojtaba G, Alireza MJ, Ali MM: Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):447-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran.
  • Cytogenetic analysis performed at diagnosis is considered to be the most valuable prognostic factor in acute non-lymphocytic leukemia (ANLL), a very heterogeneous disease.
  • Therefore, cytogenetic investigations were performed for 58 patients with various subtypes of ANLL with unstimulated short term culture and high resolution cell synchronization techniques.
  • Further prospective studies are warranted to precisely elucidate ethnic differences in the pathogenesis of this disease in different populations.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Iran / epidemiology. Karyotyping. Leukemia, Promyelocytic, Acute / epidemiology. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059342.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Thailand
  •  go-up   go-down


11. Hamilton A, Gallipoli P, Nicholson E, Holyoake TL: Targeted therapy in haematological malignancies. J Pathol; 2010 Mar;220(4):404-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For acute myeloid leukaemia, the introduction of ATRA and myelotarg have had major impacts on the design of therapy regimens and many novel targeted agents, including farnesyl transferase, FLT3 and histone deacetylase inhibitors, are now in clinical trial.
  • In lymphoid malignancies the highlight has been the introduction of rituximab, with significant improvements in the management of non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
  • The last 10 years has experienced a rapidly expanding interest and acceptance that leukaemic stem cells, including an improved ability to target them, may hold the key to improved response and reduced relapse rates across both myeloid and lymphoid disease.
  • [MeSH-minor] Drug Delivery Systems / methods. Drug Design. Humans. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / genetics. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041451.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600782
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 181
  •  go-up   go-down


12. Gottardi M, Gattei V, Degan M, Bomben R, Zucchetto A, Tecchio C, Laurino L, Zanatta L, Dei Tos AP, Mordacchini M, Canal F, Gherlinzoni F: Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones. Leuk Lymphoma; 2006 May;47(5):885-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones.
  • The simultaneous appearance of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) has been rarely reported, with AML occurring more frequently as a secondary event in patients receiving cytotoxic drugs for a primary lymphoproliferative disorder.
  • To establish whether the two neoplastic cell populations shared some common molecular signature, we performed IgH gene rearrangement studies on CD34 + /CD19- and CD34-/CD19 + immunomagnetically sorted cell populations: only genomic DNA from the CD19 + /CD34- cell fraction revealed the presence of the IgH gene rearrangement.
  • [MeSH-major] Cell Proliferation. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Myeloid / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Acute Disease. Aged. Clone Cells / pathology. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Male


13. Miller AL, Komak S, Webb MS, Leiter EH, Thompson EB: Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids. Cancer Cell Int; 2007 Nov 28;7:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By activating the glucocorticoid receptor (GR), GCs evoke apoptosis through transcriptional regulation of a complex, interactive gene network over a period of time preceding activation of the apoptotic enzymes.
  • Pediatric CD4+/CD8+ T-cell leukemia was represented by 3 CEM clones: two sensitive, CEM-C7-14 and CEM-C1-6, and one resistant, CEM-C1-15, to Dex.
  • GC-sensitive pediatric B-cell leukemia was represented by the SUP-B15 line and adult B-cell leukemia by RS4;11 cells.
  • Kasumi-1 cells gave an example of the rare Dex-sensitive acute myeloblastic leukemia (AML).
  • To test the generality of the correlations in malignant cell gene sets, we compared with GC effects on mouse non-transformed thymocytes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Growth Differ. 1995 May;6(5):505-13 [7647033.001]
  • [Cites] Leuk Res. 1997 Jan;21(1):45-50 [9029185.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3684-93 [9721879.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1807-17 [9885901.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]
  • [Cites] Cell Death Differ. 1999 Dec;6(12):1182-9 [10637434.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4324-36 [11466613.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1346-58 [11857078.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2283-93 [11884613.001]
  • [Cites] Neoplasia. 2002 Jan-Feb;4(1):68-81 [11922393.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1254-61 [12054511.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):277-84 [12519866.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23861-7 [12676946.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27053-8 [12736248.001]
  • [Cites] Genomics. 2003 Jun;81(6):543-55 [12782123.001]
  • [Cites] Recent Prog Horm Res. 2003;58:175-97 [12795419.001]
  • [Cites] Cancer. 1965 Apr;18:522-9 [14278051.001]
  • [Cites] Eur J Endocrinol. 2004 Jan;150(1):41-7 [14713278.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20858-65 [14996839.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):49-55 [15130510.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55809-17 [15509554.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2519-26 [15572593.001]
  • [Cites] Ann Acad Med Singapore. 2004 Sep;33(5 Suppl):S21-2 [15651190.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6050-6 [16115950.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4131-8 [16118324.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1903-13 [16301999.001]
  • [Cites] Leukemia. 2006 Jun;20(6):987-93 [16598301.001]
  • [Cites] FEBS Lett. 2006 Jun 12;580(14):3539-44 [16730715.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Nov;319(2):887-97 [16914556.001]
  • [Cites] J Dermatol. 2006 Oct;33(10):662-9 [17040494.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39051-61 [17062574.001]
  • [Cites] Leukemia. 2007 Feb;21(2):281-7 [17151701.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Ann Rheum Dis. 2007 Oct;66(10):1289-95 [17267514.001]
  • [Cites] Cancer Cell Int. 2007;7:3 [17391526.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4482-90 [17483364.001]
  • [Cites] Steroids. 2007 Sep;72(9-10):673-81 [17606285.001]
  • [Cites] Blood. 1991 May 1;77(9):2031-6 [2018839.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991 May;38(5):561-8 [2039752.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2876-9 [3162827.001]
  • [Cites] Blood. 1985 Jan;65(1):21-31 [3917311.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):241-6 [3926660.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1771-8 [7564524.001]
  • (PMID = 18045478.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA041407
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2228275
  •  go-up   go-down


14. Tabata M, Kai S, Satake A, Wakae T, Toda A, Chin M, Nishioka K, Tanaka H, Itsukuma T, Yamaguchi M, Okada M, Takatsuka H, Misawa M, Hara H: Relationships between hematological recovery and overall survival in older adults undergoing allogeneic bone marrow transplantation. Intern Med; 2005 Jan;44(1):35-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The advancement of hematopoietic stem cell transplantation techniques and the increase in frequency of hematological malignancy in older patients are expected to expand the indications to include more elderly patients.
  • There were 8 cases of acute myelogenous leukemia (AML), 5 cases of acute lymphocytic leukemia (ALL), 6 cases of chronic myelogenous leukemia (CML) and 2 cases of myelodysplastic syndrome (MDS).
  • We did not observe any severe graft-versus-host disease (GVHD) or regimen-related toxicities.
  • [MeSH-minor] Adult. Cause of Death. Female. Graft vs Host Disease / mortality. Humans. Leukocyte Count. Male. Middle Aged. Neutrophils. Platelet Count. Retrospective Studies


15. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W: Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One; 2010 Dec 28;5(12):e15262
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.
  • Recent data suggests that Hh signaling plays a role in normal B-cell development, and we hypothesized that Hh signaling may be important in precursor B-cell acute lymphocytic leukemia (B-ALL).
  • We found that the expression of Hh pathway components was common in human B-ALL cell lines and clinical samples.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23 [10430905.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1814-23 [17536012.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] J Biol Chem. 2007 Dec 28;282(52):37370-7 [17895245.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):238-49 [18772113.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6646-9 [18842035.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2383-6 [19052992.001]
  • [Cites] Genes Dev. 2009 Jan 1;23(1):24-36 [19136624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):776-9 [19169242.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Blood. 2009 Jul 30;114(5):995-1004 [19483124.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6007-10 [19638582.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Anticancer Res. 2009 Nov;29(11):4629-32 [20032413.001]
  • [Cites] EMBO Mol Med. 2009 Sep;1(6-7):338-51 [20049737.001]
  • [Cites] Leukemia. 2010 May;24(5):1025-36 [20200556.001]
  • [Cites] Clin Cancer Res. 2010 Jun 15;16(12):3130-40 [20530699.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Cell. 1996 Nov 15;87(4):661-73 [8929535.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):975-85 [16293577.001]
  • (PMID = 21203400.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075826; United States / NCI NIH HHS / CA / P01 CA015396; United States / NCI NIH HHS / CA / R01 CA127574; United States / NCI NIH HHS / CA / R01CA127574; United States / NCI NIH HHS / CA / R01 CA127574-05; United States / NHLBI NIH HHS / HL / HL83077; United States / NHLBI NIH HHS / HL / HL75826; United States / NHLBI NIH HHS / HL / R01 HL083077; United States / NHLBI NIH HHS / HL / T32 HL086345; United States / NCI NIH HHS / CA / P01CA15396
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / IPI-926; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / Veratrum Alkaloids; EC 1.2.1.3 / Aldehyde Dehydrogenase; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3011010
  •  go-up   go-down


16. Adelman AS, McLaughlin CC, Wu XC, Chen VW, Groves FD: Urbanisation and incidence of acute lymphocytic leukaemia among United States children aged 0-4. Br J Cancer; 2005 Jun 6;92(11):2084-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urbanisation and incidence of acute lymphocytic leukaemia among United States children aged 0-4.
  • Acute lymphocytic leukaemia (ALL) incidence among children under 5 years of age was examined, utilising data from 24 United States cancer registries.
  • [MeSH-major] Cities. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Registries / statistics & numerical data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 2001 Jul;55(7):508-14 [11413183.001]
  • [Cites] Med J Aust. 1980 Aug 9;2(3):154-5 [6932561.001]
  • [Cites] Biometrics. 1986 Dec;42(4):693-734 [3814721.001]
  • [Cites] Lancet. 1990 Dec 15;336(8729):1461-5 [1979091.001]
  • [Cites] Br J Cancer. 1991 Mar;63(3):424-9 [2003985.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):383-8 [8547535.001]
  • [Cites] Paediatr Perinat Epidemiol. 1996 Oct;10(4):411-7 [8931055.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):842-9 [9514068.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):587-91 [9758111.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):144-51 [10487626.001]
  • (PMID = 15886703.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361799
  •  go-up   go-down


17. Reddy H, Jamil K: Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in an Indian population. Leuk Lymphoma; 2006 Jul;47(7):1333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in an Indian population.
  • Acute lymphocytic leukemia (ALL) is the most common pediatric cancer worldwide, and is particularly more common in the Indian population.
  • Hence, research is increasingly examining the factors involved in disease development.
  • [MeSH-major] Genetic Predisposition to Disease. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Jul;47(7):1203-4 [16923547.001]
  • (PMID = 16923565.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


18. Montillo M, Ricci F, Miqueleiz S, Tedeschi A, Morra E: Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics; 2008 Mar;2(1):41-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).
  • The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients.
  • Pre-treatment anti-pyretics and anti-histamines are recommended to prevent or mitigate the acute infusional reactions associated with intravenous infusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1435-6 [16219582.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2971-9 [15738539.001]
  • [Cites] Haematologica. 2005 Mar;90(3):410-2 [15749678.001]
  • [Cites] Immunology. 1998 Nov;95(3):427-36 [9824507.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):319-22 [7904047.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:43-9 [8097654.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):812; author reply 813 [8094888.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Eur J Immunol. 1993 May;23(5):1098-104 [8477804.001]
  • [Cites] N Engl J Med. 1992 Oct 8;327(15):1056-61 [1355853.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Blood. 1989 Jul;74(1):19-25 [2473795.001]
  • [Cites] Br J Haematol. 1986 Nov;64(3):479-86 [3539172.001]
  • [Cites] Cancer Treat Rep. 1979 Mar;63(3):441-7 [371799.001]
  • [Cites] Cancer. 1974 Feb;33(2):555-62 [4812772.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2269-73 [15512816.001]
  • [Cites] Blood. 2004 Aug 15;104(4):948-55 [15090452.001]
  • [Cites] Blood. 2004 Aug 1;104(3):655-8 [15073032.001]
  • [Cites] Blood. 2004 Jul 15;104(2):478-86 [15044252.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1093-101 [15071604.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2 [14695424.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):773-8 [12910522.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S11-9 [12180487.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):452-3 [12167696.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1007-11 [12148879.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30 [17026823.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2827-35 [16809617.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1441-5 [16738694.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):75-80 [11842392.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Hematol J. 2001;2(5):300-6 [11920265.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2245-7 [11877305.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • (PMID = 19707426.001).
  • [ISSN] 1177-5475
  • [Journal-full-title] Biologics : targets & therapy
  • [ISO-abbreviation] Biologics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2727786
  • [Keywords] NOTNLM ; alemtuzumab / chronic lymphocytic leukemia / fludarabine
  •  go-up   go-down


19. Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S: The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant; 2008 Nov;14(11):1288-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
  • Reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation is increasingly considered for patients with chronic lymphocytic leukemia (CLL).
  • To investigate the impact of in vivo T cell depletion with alemtuzumab on the incidence of graft-versus-host disease (GVHD), nonrelapse mortality (NRM), progression-free survival (PFS), and overall survival (OS), we retrospectively analyzed the outcomes of 62 consecutive CLL patients conditioned with fludarabine and melphalan at 4 institutions.
  • Grade III-IV acute GVHD (aGVHD) was observed in 20% and 38% of patients from cohorts 1 and 2, respectively (P=.14).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphocyte Depletion. Transplantation Conditioning
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Cohort Studies. Cyclosporine / administration & dosage. Cytomegalovirus. Cytomegalovirus Infections. Disease-Free Survival. Donor Selection. Female. Humans. Immunosuppressive Agents / administration & dosage. Living Donors. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Survival Rate. T-Lymphocytes. Transplantation, Homologous. Virus Activation / drug effects

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biol Blood Marrow Transplant. 2009 Apr;15(4):517-8 [19285641.001]
  • (PMID = 18940684.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 3A189DH42V / alemtuzumab; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


20. Klotz J, Bryant P, Wilcox HB, Dillon M, Wolf B, Fagliano J: Population-based retrieval of newborn dried blood spots for researching paediatric cancer susceptibility genes. Paediatr Perinat Epidemiol; 2006 Sep;20(5):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incident cases of acute lymphocytic leukaemia and population-based controls were ascertained.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Glutathione Transferase / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911024.001).
  • [ISSN] 0269-5022
  • [Journal-full-title] Paediatric and perinatal epidemiology
  • [ISO-abbreviation] Paediatr Perinat Epidemiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


21. Auffermann-Gretzinger S, Eger L, Schetelig J, Bornhäuser M, Heidenreich F, Ehninger G: Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation; 2007 May 15;83(9):1268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
  • The antibody alemtuzumab (anti-CD52) is effective in preventing acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (aHSCT).
  • To determine whether this second mechanism of action is significant, we investigated the effects of intravenous alemtuzumab by comparing skin and blood DC numbers of patients with chronic lymphocytic leukemia, before and after a 4-week course of alemtuzumab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Blood Cells / pathology. Dendritic Cells / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496545.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


22. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We studied the relationship between molecular-cytogenetic abnormalities and T-cell development stage to investigate whether arrest at specific stages can explain the prognostic significance of specific abnormalities.
  • Classification into T-cell developmental subgroups was not predictive for outcome.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Lineage. Child. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Mutation / genetics. Oncogene Proteins, Fusion / genetics. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


23. Maruo T, Namikawa K, Kunihiro A, Lynch J, Shida T, Kishikawa S: Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog. J S Afr Vet Assoc; 2009 Dec;80(4):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog.
  • Examination of Wright-Giemsa-stained films of peripheral blood revealed the presence of large granular lymphocytes (LGL).
  • Seventy-two per cent (81360/ml) of the lymphocytes were found to be 12-17 microm in diameter, containing nuclei with mature clumped chromatin and abundant lightly basophilic cytoplasm with a variable number of fine azurophilic granules.
  • As a result of multiple-agent chemotherapy, the markedly elevated levels of lymphocytes gradually decreased to 7500/ml on day 122 and the patient maintained a good quality of life for the following 3 months.
  • Shortly after diagnosis, the dog developed sudden onset of central nervous system signs and died on day 270.
  • A common outcome of canine LGL is the development of acute blast crisis or lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Histiocytic Sarcoma / veterinary. Leukemia, Large Granular Lymphocytic / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458870.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Robak T: Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs; 2005;19(1):9-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in the treatment of chronic lymphocytic leukemia.
  • Alemtuzumab is a humanized therapeutic monoclonal antibody (MAb) that recognizes the CD52 antigen, expressed on normal and neoplastic lymphocytes, monocytes, and natural killer cells.
  • In 2001, alemtuzumab was approved in the US and Europe to treat B-cell chronic lymphocytic leukemia (CLL) that had been treated previously with alkylating agents and was refractory to fludarabine.
  • Alemtuzumab can also be used in patients with CLL as a preparative regimen for stem cell transplantation (SCT) and to prevent graft versus host disease.
  • Moreover its in vivo use before or after SCT may also potentially result in depletion of residual leukemia cells, especially in the autologous setting.
  • Adverse events associated with alemtuzumab include acute first-dose reaction, hematologic toxicity, and infectious complications.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Half-Life. Humans. Infusions, Intravenous. Middle Aged. Rituximab. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691213.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 99
  •  go-up   go-down


25. Uckun FM, Dibirdik I, Qazi S, Yiv S: Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung; 2010;60(4):210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
  • Notably, WHI-P131-NP was capable of causing apoptotic death in primary leukemia cells from chemotherapy-resistant acute lymphoblastic leukemia (ALL) as well as chronic lymphocytic leukemia (CLL) patients.
  • These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target.
  • [MeSH-major] Antineoplastic Agents. Janus Kinase 3 / antagonists & inhibitors. Leukemia, B-Cell / drug therapy. Leukemia, Biphenotypic, Acute / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / pharmacology. Quinazolines / administration & dosage. Quinazolines / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calibration. Cell Lineage. Chemistry, Pharmaceutical. Chromatography, High Pressure Liquid. Female. Humans. Liposomes. Mice. Mice, SCID. Nanoparticles. Osmolar Concentration. Particle Size

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arzneimittelforschung. 2010;60(5):286
  • (PMID = 20486472.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / WHI P131; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


26. Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL: Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer; 2009 Dec 15;53(7):1249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5 [11502805.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):557-68 [12754700.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Pediatrics. 2003 Aug;112(2):424-30 [12897303.001]
  • [Cites] Arch Dis Child. 2003 Sep;88(9):748-52 [12937090.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1141-51 [14513062.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Arch Dis Child. 1994 Aug;71(2):147-9 [7944537.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Pediatr Res. 1995 Jul;38(1):86-90 [7478803.001]
  • [Cites] Stat Med. 1997 Aug 30;16(16):1859-71 [9280038.001]
  • [Cites] Int J Cancer Suppl. 1998;11:81-4 [9876486.001]
  • [Cites] Eur J Clin Nutr. 2005 Mar;59(3):419-25 [15674315.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1725-9 [15754333.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1730-9 [15761876.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] Am J Clin Nutr. 2006 Jan;83(1):70-4 [16400052.001]
  • [Cites] J Pediatr Oncol Nurs. 2006 May-Jun;23(3):135-42 [16624889.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Psychooncology. 2007 May;16(5):448-57 [16915562.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2063-9 [17513811.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Apr-May;17(3):231-7 [10779989.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • (PMID = 19688832.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01; United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS144355; NLM/ PMC3044478
  •  go-up   go-down


27. Isabel J, Champion JC: Junctional escape rhythm secondary to acute hyperkalemic renal failure in the setting of concurrent beta-blocker therapy. JAAPA; 2006 Dec;19(12):78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Junctional escape rhythm secondary to acute hyperkalemic renal failure in the setting of concurrent beta-blocker therapy.
  • [MeSH-minor] Aged. Angiotensin-Converting Enzyme Inhibitors / adverse effects. Diuretics / adverse effects. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male

  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243264.001).
  • [ISSN] 1547-1896
  • [Journal-full-title] JAAPA : official journal of the American Academy of Physician Assistants
  • [ISO-abbreviation] JAAPA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Diuretics; 27O7W4T232 / Spironolactone
  •  go-up   go-down


28. Dunphy CH: Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med; 2006 Apr;130(4):483-520
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications.
  • OBJECTIVES: To review the literature regarding GE data that may provide important information regarding pathogenesis and that may be extrapolated for use in diagnosing and prognosticating lymphomas and leukemias; to present GE findings in Hodgkin and non-Hodgkin lymphomas, acute leukemias, and chronic myeloid leukemia in detail; and to summarize the practical clinical applications in tables that are referenced throughout the text.
  • CONCLUSIONS: Gene expression profiling of lymphomas and leukemias aids in the diagnosis and prognostication of these diseases.
  • Flow cytometric and immunohistochemical applications of the information gained from GE profiling assist in the management of chronic lymphocytic leukemia, other low-grade B-cell non-Hodgkin lymphomas and leukemias, diffuse large B-cell lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and classic Hodgkin lymphoma.
  • For practical clinical use, GE profiling of precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, and acute myeloid leukemia has supported most of the information that has been obtained by cytogenetic and molecular studies (except for the identification of FLT3 mutations for molecular analysis), but extrapolation of the analyses leaves much to be gained based on the GE profiling data.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / genetics. Lymphoma / diagnosis. Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594743.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 173
  •  go-up   go-down


29. Thomas P, Fenech M: Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease. Vitam Horm; 2008;79:375-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease.
  • Certain common polymorphisms within the MTHFR gene (C677T, A1298C) result in reduced enzymatic activity and have been associated with reduced risk for a variety of cancers such as acute lymphocytic leukemia, lung and colorectal cancer.
  • These common polymorphisms are also associated with hyperhomocysteinemia that has been reported to be an increased risk factor for neural tube defects and cardiovascular disease.
  • [MeSH-minor] Continental Population Groups / genetics. Female. Genetic Predisposition to Disease. Genomic Instability. Humans. Nutritional Status. Polymorphism, Genetic. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804702.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


30. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer; 2006 Jan 1;106(1):120-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
  • BACKGROUND: Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months.
  • Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19% had failed standard induction chemotherapy, and 50% had Philadelphia chromosome-positive disease.
  • Five patients (36%) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Apr 1;106(7):1641
  • (PMID = 16331634.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 0 / Sphingomyelins; 5J49Q6B70F / Vincristine
  •  go-up   go-down


31. Howard AN, Bridges KA, Meyn RE, Chandra J: ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. Cancer Chemother Pharmacol; 2009 Dec;65(1):41-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or its less active stereoisomer.
  • Combining ABT-737 with ROS-inducing agents such as adaphostin or etoposide enhanced cell death.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404643.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115811; United States / NCI NIH HHS / CA / R01 CA69003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABT-737; 0 / Biphenyl Compounds; 0 / Nitrophenols; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 0 / Sulfonamides; 11062-77-4 / Superoxides; BBX060AN9V / Hydrogen Peroxide; EC 3.4.22.- / Caspases; GAN16C9B8O / Glutathione
  •  go-up   go-down


32. Caudill JS, Porcher JC, Steensma DP: Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk Lymphoma; 2008 May;49(5):989-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.
  • We analysed the splicing repertoire of CDC25C- a gene localised to chromosome 5q31 and encoding a cyclin/cyclin-dependent-kinase regulatory phosphatase critical for cell cycle checkpoint control - in MDS, acute myeloid leukemia, chronic lymphocytic leukemia and healthy tissues.
  • [MeSH-minor] Case-Control Studies. Cell Cycle. Chromosomes, Human, Pair 5. Humans. Protein Isoforms. RNA Precursors


33. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, Dzekunov S, Peshwa M: Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther; 2010 Mar;17(3):147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells.
  • Transfection of eGFP mRNA into ex vivo expanded NK cells (N=5) or purified unstimulated NK cells from peripheral blood (N=4) resulted in good cell viability with eGFP expression in 85+/-6% and 86+/-4%, 24 h after transfection, respectively.
  • Ex vivo expanded and purified unstimulated NK cells expressing anti-CD19-BB-z exhibited enhanced cytotoxicity against CD19(+) target cells resulting in > or =80% lysis of acute lymphoblastic leukemia and B-lineage chronic lymphocytic leukemia cells at effector target ratios lower than 10:1.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2003 Mar 1;274(1-2):245-56 [12609550.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] J Immunol Methods. 2003 Nov;282(1-2):93-102 [14604544.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):104-13 [14688315.001]
  • [Cites] J Immunol Methods. 2004 Jan;284(1-2):133-40 [14736423.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Methods. 2004 Jun;33(2):126-35 [15121167.001]
  • [Cites] Exp Hematol. 2004 Jun;32(6):536-46 [15183894.001]
  • [Cites] Curr Hematol Rep. 2005 Jan;4(1):64-72 [15610662.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Feb 4;327(1):356-60 [15629470.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Cytotherapy. 2005;7(1):16-22 [16040380.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):151-9 [16140584.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):215-24 [16082377.001]
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Cytotherapy. 2006;8(2):105-17 [16698684.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1835-8 [15457184.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1986;105:176-256 [3541139.001]
  • [Cites] Biophys J. 1990 Jul;58(1):13-9 [2200534.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1731-7 [8142640.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(11):1057-63 [9877267.001]
  • [Cites] Adv Exp Med Biol. 1998;452:13-8 [9889954.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):302-9 [16809159.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1819-28 [16932339.001]
  • [Cites] Hum Gene Ther. 2006 Oct;17(10):1027-35 [17007566.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4009-17 [16940422.001]
  • [Cites] Curr Opin Oncol. 2007 Mar;19(2):142-7 [17272987.001]
  • [Cites] Transfusion. 2007 Mar;47(3):520-8 [17319835.001]
  • [Cites] Haematologica. 2007 Mar;92(3):381-8 [17339188.001]
  • [Cites] J Leukoc Biol. 2007 Oct;82(4):849-60 [17626798.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):329-42 [18071952.001]
  • [Cites] Mol Immunol. 2008 Apr;45(8):2255-61 [18243319.001]
  • [Cites] Exp Cell Res. 1999 Dec 15;253(2):541-50 [10585278.001]
  • [Cites] Gene Ther. 2000 Aug;7(16):1431-7 [10981672.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] FASEB J. 2001 Mar;15(3):586-8 [11259375.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Aug;10(4):451-63 [11522229.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1155-8 [11590441.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):252-8 [12110902.001]
  • [Cites] Technol Cancer Res Treat. 2002 Oct;1(5):341-50 [12625759.001]
  • (PMID = 19745843.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113482-04; United States / NCI NIH HHS / CA / R01 CA113482; United States / NCI NIH HHS / CA / R01 CA113482-04
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Receptors, Antigen; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS154275; NLM/ PMC2821468
  •  go-up   go-down


34. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, Chilosi M, Caligaris-Cappio F, Ghia P: ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia; 2006 Apr;20(4):689-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
  • ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells.
  • ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic lymphocytic leukemia (CLL) where it correlates with clinical outcome.
  • We analyzed several B-cell lines and ex vivo malignant B cells, ranging from acute lymphoblastic leukemia to multiple myeloma and reflecting different stages of B-cell differentiation, and they showed ZAP-70 expression regardless their maturation stage.
  • We then analyzed by Western blot and flow cytometry different human normal B-lymphocyte subpopulations: naïve, germinal center and memory B cells from tonsils, CD19+ CD5+ cells from cord blood and CD19+ lymphocytes from peripheral blood.
  • In addition, ZAP-70 expression levels could be modulated following stimulation via the B-cell receptor.
  • These findings implicate a potential role of ZAP-70 in the signalling pathway of B lymphocytes at different maturational stages, indicate that ZAP-70 expression is not a CLL-specific feature among B-cell malignancies and suggest that the absence of ZAP-70 rather than its presence should be considered abnormal for malignant B lymphocytes.
  • [MeSH-major] B-Lymphocyte Subsets / metabolism. Gene Expression Regulation. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. ZAP-70 Protein-Tyrosine Kinase / biosynthesis. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Antigens, CD / biosynthesis. Blotting, Western. Cell Differentiation. Cell Line. Cells, Cultured. Flow Cytometry. Humans. Sensitivity and Specificity. Signal Transduction

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482211.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


35. Whitworth KW, Symanski E, Coker AL: Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004. Environ Health Perspect; 2008 Nov;116(11):1576-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We adjusted models for age, sex, race/ethnicity, and community-level socioeconomic status (cSES).
  • RESULTS: Census tracts with the highest benzene levels had elevated rates of all leukemia [rate ratio (RR) = 1.37; 95% confidence interval (CI), 1.05, 1.78].
  • This association was higher for acute myeloid leukemia (AML) (RR = 2.02; 95% CI, 1.03-3.96) than for acute lymphocytic leukemia (ALL) (RR = 1.24; 95% CI, 0.92-1.66).
  • Among census tracts with the highest 1,3-butadiene levels, we observed RRs of 1.40 (95% CI, 1.07-1.81), 1.68 (95% CI, 0.84-3.35), and 1.32 (95% CI, 0.98-1.77) for all leukemia, AML, and ALL, respectively.
  • CONCLUSIONS: Our ecologic analysis suggests an association between childhood leukemia and hazardous air pollution; further research using more sophisticated methodology is warranted.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Air Waste Manag Assoc. 2000 Feb;50(2):175-80 [10680346.001]
  • [Cites] Occup Environ Med. 1999 Nov;56(11):774-80 [10658564.001]
  • [Cites] J Am Stat Assoc. 1995 Mar;90(429):64-71 [12155398.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):665-73 [12296514.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):386-91 [12843760.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):596-9 [14696126.001]
  • [Cites] Environ Health Perspect. 2004 Feb;112(2):257-65 [14754581.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):773-8 [15317919.001]
  • [Cites] Environ Health Perspect. 2004 Oct;112(14):1386-92 [15471730.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1982 May;29:1-398 [6957379.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:105-10 [8549455.001]
  • [Cites] J Epidemiol Community Health. 1995 Dec;49 Suppl 2:S20-7 [8594128.001]
  • [Cites] Milbank Q. 1996;74(2):215-38 [8632735.001]
  • [Cites] Int Arch Occup Environ Health. 1997;70(1):57-60 [9258708.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1999;71 Pt 1:1-315 [10507919.001]
  • [Cites] Science. 2004 Dec 3;306(5702):1774-6 [15576619.001]
  • [Cites] J Epidemiol Community Health. 2005 Feb;59(2):101-5 [15650139.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] J Epidemiol Community Health. 2005 Sep;59(9):755-60 [16100313.001]
  • [Cites] Mutat Res. 2006 Jan;612(1):14-39 [16027031.001]
  • [Cites] J Epidemiol Community Health. 2006 Feb;60(2):136-41 [16415262.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2920-9 [16425269.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2006 Nov;16(6):538-43 [16736057.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1388-93 [17938725.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2008 Jan;18(1):45-58 [17878926.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:13-8 [8549460.001]
  • [Cites] Am J Epidemiol. 2001 Mar 1;153(5):433-43 [11226975.001]
  • (PMID = 19057714.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128106; United States / NCI NIH HHS / CA / 1 R03 CA128106-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants
  • [Other-IDs] NLM/ PMC2592281
  • [Keywords] NOTNLM ; 1,3-butadiene / air toxics / benzene / childhood cancer / epidemiology / hazardous air pollution
  •  go-up   go-down


36. Lai LT, Lee DC, Ko W, Shevde K, Zhang M: Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia. Int J Cardiol; 2010 Mar 4;139(2):e24-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia.
  • In the present case, a patient with MBL deficiency underwent coronary artery bypass grafting (CABG) after an acute MI with underlining chronic lymphocytic leukemia (CLL).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Mannose-Binding Lectin / blood. Mannose-Binding Lectin / deficiency. Myocardial Infarction / complications. Myocardial Infarction / surgery

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] J Exp Med. 2005 Jan 3;201(1):117-25 [15623574.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):959-60 [9752823.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):260-7 [15254284.001]
  • [Cites] Circulation. 2004 Feb 3;109(4):471-5 [14732744.001]
  • [Cites] Biochem Soc Trans. 2003 Aug;31(Pt 4):748-52 [12887296.001]
  • [Cites] Cardiology. 2002;98(3):123-6 [12417810.001]
  • [Cites] Mol Immunol. 2001 Aug;38(2-3):133-49 [11532276.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1549-56 [10793066.001]
  • [Cites] Stroke. 2005 May;36(5):944-8 [15790942.001]
  • [Cites] Transfusion. 2008 Apr;48(4):601-8 [18194386.001]
  • [Cites] Ann Thorac Surg. 2008 Feb;85(2):530-5 [18222258.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jul;56(7):959-71 [17131120.001]
  • [Cites] Genet Epidemiol. 2007 Jan;31(1):31-41 [17096357.001]
  • [Cites] Clin Exp Immunol. 2006 May;144(2):239-46 [16634797.001]
  • [Cites] Eur Heart J. 2005 Aug;26(16):1660-5 [15821010.001]
  • (PMID = 19038464.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R21 HL088527; United States / NHLBI NIH HHS / HL / R21 HL088527-01A1; United States / NHLBI NIH HHS / HL / R21 HL088527-02
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin
  • [Other-IDs] NLM/ NIHMS352756; NLM/ PMC3279176
  •  go-up   go-down


37. Sudhakar N, Nirmala K, Rajalekshmy KR, Rajkumar T: Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients? Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients?
  • BACKGROUND: The incidence of T-cell acute lymphoblastic leukemia (T-ALL) in South India is very high (43.1%) when compared to the Western countries (10-20%).
  • Comparing the clinical features and immunological marker analysis of TAL-1 deletion positive and negative cases did not show any significant differences except in the WBC count, which was significantly higher in cases showing TAL-1 deletion (>100 x 109/L, p value= 0.003).
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439091.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


38. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM: Reprogramming of miRNA networks in cancer and leukemia. Genome Res; 2010 May;20(5):589-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reprogramming of miRNA networks in cancer and leukemia.
  • We also built, for the first time, specialized miRNA networks for solid tumors and leukemias.
  • Other miRNAs, such as hsa-miR-30 and hsa-miR-204, were found to be physically altered at the DNA copy number level as well.
  • Finally, we experimentally validated the miRNA network with acute lymphocytic leukemia originated in Mir155 transgenic mice.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia. MicroRNAs / genetics. Neoplasms
  • [MeSH-minor] Adenocarcinoma / metabolism. Animals. Cell Line, Tumor. Gene Dosage. Humans. Lung / metabolism. Lung Neoplasms / metabolism. Mice. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


39. Russell EB: Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol; 2005 Sep;32(9):1760-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Criteria used for diagnosis of RS3PE syndrome included sudden onset of painful diffuse swelling of both hands associated with pitting edema of the dorsa of the hands without other synovitis or evidence of disease, negative rheumatoid factor, absence of radiologic abnormalities, and resolution within 6-12 months without sequelae.
  • Four had a cancer diagnosed following recognition of the RS3PE syndrome; 1 patient developed non-Hodgkin's lymphoma initially diagnosed as hairy cell leukemia after 4 years; 1 developed acute lymphocytic leukemia with hyperdiploidy after 14 years; 1 was diagnosed with male breast cancer after 2.5 years; and 1 developed squamous cell lung cancer 12 months after RS3PE diagnosis.
  • The interval between onset of RS3PE syndrome and diagnosis of cancer was fairly long, indicating that patients should be monitored for neoplasia with prudent age and sex specific surveillance for an extended period after diagnosis with RS3PE.

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Synovitis.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Rheumatol. 2006 Nov;33(11):2365-6; author reply 2366 [17086622.001]
  • [CommentIn] J Rheumatol. 2007 Feb;34(2):452-3 [17304672.001]
  • (PMID = 16142875.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


40. Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T, Yamanishi K: Development of varicella vaccine. J Infect Dis; 2008 Mar 1;197 Suppl 2:S41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the follow-up of vaccinated children with acute lymphocytic leukemia, the incidence of herpes zoster (HZ) was significantly lower among children who did not have a rash after vaccination, compared with those who had a rash caused by VZV (6 [2.3%] of 260 vs. 12 [17.1%] of 70, respectively).

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419406.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chickenpox Vaccine
  •  go-up   go-down


41. Stat bite: Estimated new leukemia cases in 2008. J Natl Cancer Inst; 2008 Apr 16;100(8):531
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stat bite: Estimated new leukemia cases in 2008.
  • [MeSH-major] Leukemia / epidemiology
  • [MeSH-minor] Humans. Incidence. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398092.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Burghardt KM, Leonard M, Feber J, Halton J, Filler G: Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer; 2006 Apr;46(4):512-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia.
  • A 14-month-old infant presented with gastroenteritis with febrile pancytopenia and was diagnosed with acute lymphocytic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ciprofloxacin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pseudomonas Infections / diagnosis. Ureteral Obstruction / surgery. Urinary Tract Infections / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929136.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5E8K9I0O4U / Ciprofloxacin
  •  go-up   go-down


43. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM: Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene; 2005 Aug 11;24(34):5396-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
  • The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis.
  • Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia.
  • Less is known concerning acute leukemia.
  • One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis.
  • We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation.
  • As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines.
  • We then directly addressed the role played by both isoforms in this type of leukemia.
  • Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007226.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-01A3; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-01A3
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / RNA, Small Interfering; 0 / WNT16 protein, human; 0 / Wnt Proteins
  •  go-up   go-down


44. Ollila HM, Soronen P, Silander K, Palo OM, Kieseppä T, Kaunisto MA, Lönnqvist J, Peltonen L, Partonen T, Paunio T: Findings from bipolar disorder genome-wide association studies replicate in a Finnish bipolar family-cohort. Mol Psychiatry; 2009 Apr;14(4):351-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors. Cohort Studies. Diacylglycerol Kinase. Finland. Genome-Wide Association Study. Humans. Membrane Proteins / genetics. Nuclear Proteins. Polymorphism, Single Nucleotide / genetics. Proto-Oncogene Proteins. Receptors, Cell Surface. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genet Epidemiol. 2004 Jan;26(1):61-9 [14691957.001]
  • [Cites] J Neurochem. 2004 Mar;88(6):1470-6 [15009648.001]
  • [Cites] JAMA. 1989 Oct 6;262(13):1834-41 [2674489.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Biol Psychiatry. 2008 Sep 1;64(5):438-42 [18466879.001]
  • [Cites] Mol Psychiatry. 2008 Feb;13(2):197-207 [17486107.001]
  • [Cites] Mol Psychiatry. 2008 May;13(5):466-7 [18421293.001]
  • [Cites] Mol Psychiatry. 2008 Jun;13(6):558-69 [18317468.001]
  • [Cites] Mol Psychiatry. 2008 Jul;13(7):649-53 [18504426.001]
  • [Cites] Hum Mol Genet. 2007 Oct 15;16(20):2517-28 [17673452.001]
  • (PMID = 19308021.001).
  • [ISSN] 1476-5578
  • [Journal-full-title] Molecular psychiatry
  • [ISO-abbreviation] Mol. Psychiatry
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 089061
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DFNB31 protein, human; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / PALB2 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SORCS2 protein, human; 0 / Tumor Suppressor Proteins; 135471-20-4 / TAL1 protein, human; EC 2.7.1.107 / Diacylglycerol Kinase
  • [Other-IDs] NLM/ PMC2694406; NLM/ UKMS4946
  •  go-up   go-down


45. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM: Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem; 2005 Jul 1;280(26):24315-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage.
  • Chromosomal translocations involving the mixed lineage leukemia (MLL) gene are often observed in acute leukemias of both myeloid and lymphocytic origin.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. DNA Primers / chemistry. Humans. Immunoprecipitation. Luciferases / metabolism. Models, Genetic. Myeloid-Lymphoid Leukemia Protein. Plasmids / metabolism. Protein Structure, Tertiary. RNA / chemistry. Radiation, Ionizing. Recombinant Fusion Proteins / chemistry. Retroviridae / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic. Transcriptional Activation. Transfection. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851483.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES11627; United States / NCI NIH HHS / CA / R01 CA85679-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / MLL-AF10 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / MLL-ELL fusion protein, human; 0 / MLL-ENL oncoprotein, human; 0 / Oncogene Proteins, Fusion; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Protein p53; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 63231-63-0 / RNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


46. Chan WY, Follows GA, Lacaud G, Pimanda JE, Landry JR, Kinston S, Knezevic K, Piltz S, Donaldson IJ, Gambardella L, Sablitzky F, Green AR, Kouskoff V, Göttgens B: The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood; 2007 Mar 1;109(5):1908-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, despite coregulation of Scl and Lyl1 by the same Ets and GATA factors, Scl expression was initiated prior to Lyl1 in embryonic stem (ES) cell differentiation assays.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Cell Line. Conserved Sequence. Embryo, Mammalian / embryology. Embryo, Mammalian / metabolism. Endothelial Cells / metabolism. Gene Expression. Humans. Mice. Mice, Knockout. Molecular Sequence Data. Phenotype. Promoter Regions, Genetic / genetics. Sequence Alignment. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053063.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / GATA2 Transcription Factor; 0 / Gata2 protein, mouse; 0 / Lyl1 protein, mouse; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse
  •  go-up   go-down


47. Soliman Oel-S, Abd El-Aal Hegazi Hasan M, El-Ashry R, Zaghloul MH, Kora B: Parvovirus B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic parameters compared with nested PCR. J Pediatr Hematol Oncol; 2009 Mar;31(3):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parvovirus B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic parameters compared with nested PCR.
  • SUBJECTS AND METHODS: Fifty-nine children under chemotherapy (39 with acute lymphocytic leukemia and 20 with solid tumors) with mean age of 4.96+/-1.94 years, in addition to 30 healthy children of matched age and sex, were enrolled in this study.
  • PCR-positive patients had significantly higher frequency of unexplained anemia, red blood cell transfusions, and longer hospital stay than PCR-negative patients (P<0.001).
  • Multiple linear regression analysis showed that unexplained anemia and multiple red blood cell transfusions were the most important variables that can predict PCR positivity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262242.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antineoplastic Agents; 0 / DNA, Viral
  •  go-up   go-down


48. Carrillo C, Vizeu H, Soares-Júnior LA, Fava M, Filho VO: Dental approach in the pediatric oncology patient: characteristics of the population treated at the dentistry unit in a pediatric oncology brazilian teaching hospital. Clinics (Sao Paulo); 2010 Jun;65(6):569-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The objective of this paper was to characterize the population seen at the dentistry unit of the hematology-oncology service of the Oncology-Hematology Service, Instituto da Criança at the Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo.
  • Oral problems resulting from cancer therapy increase the risk of infection, length of hospital stay, treatment cost and negative impact on the course and prognosis of the disease.
  • The most common cancer was acute lymphocytic leukemia (32.2%).
  • The aim of implementation of the dentistry unit was to maintain good oral health and patients' quality of life, which is critical to provide oral care and prevent future oral problems.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Dental Care / statistics & numerical data. Neoplasms / drug therapy. Stomatognathic Diseases / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Dental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2001 Oct;37(7):586-92 [11564580.001]
  • [Cites] Support Care Cancer. 2009 Nov;17(11):1409-15 [19234862.001]
  • [Cites] Cancer J. 2002 May-Jun;8(3):247-54 [12074324.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):277-84 [15057287.001]
  • [Cites] Pediatr Dent. 2004 Jan-Feb;26(1):53-7 [15080359.001]
  • [Cites] J Dermatol Surg Oncol. 1981 Dec;7(12):1019-25 [7338583.001]
  • [Cites] Pediatrics. 1984 Jun;73(6):816-23 [6728583.001]
  • [Cites] Compendium. 1987 Jan;8(1):41-3, 46-7, 50 [2948648.001]
  • [Cites] Int J Oral Maxillofac Surg. 1987 Jun;16(3):376-82 [3112271.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):437-43 [2326035.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1992 Dec;74(6):749-55 [1488231.001]
  • [Cites] Compendium. 1994 Oct;15(10):1252, 1254, 1256 passim; quiz 1262 [7987891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):697-703 [9240635.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1998 Sep 15;45(1):7-13 [9804014.001]
  • [Cites] ASDC J Dent Child. 1998 Nov-Dec;65(6):468-73 [9883321.001]
  • [Cites] Dent Today. 2005 Aug;24(8):58-61; quiz 61 [16161819.001]
  • [Cites] Indian J Med Res. 2006 Oct;124(4):399-402 [17159259.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2250-5 [17053058.001]
  • [Cites] J Can Dent Assoc. 2007 Apr;73(3):257-61 [17439713.001]
  • [Cites] Clinics (Sao Paulo). 2009;64(3):193-8 [19330244.001]
  • [Cites] Cad Saude Publica. 2002 Jan-Feb;18(1):33-44 [11910422.001]
  • (PMID = 20613931.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2898549
  • [Keywords] NOTNLM ; Cancer / Dental care / Outpatient care / Pediatric dentistry
  •  go-up   go-down


49. Tamamura H, Tsutsumi H, Masuno H, Fujii N: Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr Med Chem; 2007;14(1):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chemokine receptor, CXCR4, is a GPCR that transduces signals of its endogenous ligand, CXCL12 (stromal cell-derived factor-1, SDF-1).
  • This system has recently been proven to be involved in several problematic diseases, including HIV infection, cancer cell metastasis, leukemia cell progression, rheumatoid arthritis (RA) and pulmonary fibrosis.
  • Fourteen-mer peptides, T140 and its analogs, were previously found to be specific CXCR4 antagonists that were characterized as HIV-entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents and anti-RA agents.


50. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC: A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer; 2009 Dec;53(6):978-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
  • BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis.
  • Patients with stable disease or better on day 29 could continue on to combination therapy with Campath-1H, methotrexate, and 6-mercaptopurine for two additional cycles.
  • RESULTS: One of 13 patients enrolled had a complete response to Campath-1H and 4 had stable disease.
  • Serum Campath-1H concentrations appeared to be somewhat lower in children with ALL compared with adult patients with chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2245-7 [11877305.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):249-53 [12663634.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):205-19 [15101704.001]
  • [Cites] Blood. 2004 Aug 15;104(4):948-55 [15090452.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2645-51 [16688777.001]
  • [Cites] Transpl Int. 2006 Sep;19(9):705-14 [16918530.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8 [17311819.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] J Neurol Sci. 2007 Aug 15;259(1-2):128-32 [17362994.001]
  • [Cites] Br J Clin Pharmacol. 2007 Sep;64(3):278-91 [17506867.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Immunol Methods. 2002 Feb 1;260(1-2):285-302 [11792397.001]
  • (PMID = 19637330.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452-09; United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U-01 CA97452; United States / NCI NIH HHS / CA / CA097452-09; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U-10 CA98543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ NIHMS144404; NLM/ PMC3120889
  •  go-up   go-down


51. Uzunhan Y, Cadranel J, Boissel N, Gardin C, Arnulf B, Bergeron A: [Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)]. Rev Mal Respir; 2010 Jun;27(6):599-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)].
  • We will also consider acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and hairy cell leukaemia, as well as malignant plasmocytic disorders such as myeloma, POEMS syndrome and Waldenström's macroglobulinaemia.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Multiple Myeloma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Waldenstrom Macroglobulinemia / complications

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20610075.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


52. Toedling J, Schmeier S, Heinig M, Georgi B, Roepcke S: MACAT--microarray chromosome analysis tool. Bioinformatics; 2005 May 1;21(9):2112-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate the applicability of the approach on a publicly available data set on acute lymphocytic leukemia.
  • AVAILABILITY: The R-package MACAT can be obtained from http://www.compdiag.molgen.mpg.de/software/macat.shtml SUPPLEMENTARY INFORMATION: http://www.compdiag.molgen.mpg.de/software/macat.shtml.

  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15572464.001).
  • [ISSN] 1367-4803
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Tigay JH: A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21. J Pediatr Oncol Nurs; 2009 Nov-Dec;26(6):362-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
  • Among the many aberrations caused by DS, including shortened stature and distorted facies, are several blood dyscrasias, including childhood leukemias-namely, acute myeloid leukemia (AML) and acute lymphoblastic, or lymphocytic, leukemia (ALL).
  • Other mutations are the gene fusion at TEL/AML1, and a new mutation found, which labels the Janus Kinase gene or JAK2 as on oncogenic precursor, which when associated with the B-cell precursor gene or BCP is highly leukomogenic.
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


54. Ressel A, Trümper L, Bäsecke J: [Occlusion of the femoral arteries in de novo AML]. Med Klin (Munich); 2007 May 15;102(5):388-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occlusion of the femoral arteries in de novo AML].
  • [Transliterated title] Femoralarterienverschluss bei De-novo-AML.
  • BACKGROUND: Leukemic emboli in acute (AML) and chronic myelocytic leukemia (CML) are associated with hyperleukocytosis (>100,000/microl leukocytes) and most frequently detected at autopsy.
  • CASE REPORT: A 53-year-old woman was admitted with hyperleukocytosis and acute pain in her right leg.
  • An occlusion of the right femoral arteries as the presenting symptom of a de novo AML (FAB M1/WHO: AML without maturation) with hyperleukocytosis was diagnosed.
  • CONCLUSION: Leukemic emboli of large vessels are uncommon in leukemia with hyperleukocytosis.
  • Leukemic emboli mainly occur in AML and CML in blast crisis and are rare in acute (ALL) and chronic lymphocytic leukemia (CLL).
  • [MeSH-major] Arterial Occlusive Diseases / etiology. Femoral Artery. Leukemia, Myeloid, Acute / diagnosis. Neoplastic Cells, Circulating

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497090.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y: Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir. Int J Hematol; 2007 Apr;85(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).
  • A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.
  • [MeSH-minor] Adult. Cord Blood Stem Cell Transplantation / adverse effects. DNA, Viral / blood. DNA, Viral / drug effects. Female. Humans. Injections, Intravenous. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2003 Aug;47(2):133-8 [12860147.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):1003-5 [10800071.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2101-2 [11445106.001]
  • [Cites] J Infect Dis. 1985 Dec;152(6):1172-81 [3905982.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2568-73 [10878045.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):805-7 [7670413.001]
  • [Cites] Intern Med. 2004 Sep;43(9):861-4 [15497526.001]
  • (PMID = 17483062.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; X4HES1O11F / Acyclovir
  •  go-up   go-down


56. Horino S, Rikiishi T, Niizuma H, Abe H, Watanabe Y, Onuma M, Hoshi Y, Sasahara Y, Yoshinari M, Kazama T, Hayashi Y, Kumaki S, Tsuchiya S: Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia. Int J Hematol; 2009 Nov;90(4):483-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia.
  • Immune thrombocytopenic purpura (ITP) has been associated with several hematologic malignancies such as Hodgkin and non-Hodgkin lymphomas and chronic lymphocytic leukemia, but it is rare in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Purpura, Thrombocytopenic, Idiopathic / complications. Purpura, Thrombocytopenic, Idiopathic / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Chronic Disease. Female. Humans. Splenectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Immune Thrombocytopenic Purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):372-6 [15700256.001]
  • [Cites] J Pediatr. 1979 Mar;94(3):408-9 [284111.001]
  • [Cites] J Thromb Haemost. 2003 Jul;1(7):1587-92 [12871295.001]
  • [Cites] Am J Med. 2005 Sep;118(9):1026-33 [16164890.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):139-43 [17328716.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jul;27(7):397-9 [16012332.001]
  • [Cites] Cell. 2000 May 26;101(5):455-8 [10850488.001]
  • [Cites] Eur J Haematol. 1993 Oct;51(4):259-61 [7694874.001]
  • [Cites] Haematologica. 1998 Jul;83(7):669-70 [9718878.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):336-44 [14768038.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):44-8 [9482412.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Mar;28(3):170-2 [16679943.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):477-83 [9054651.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Neth J Med. 2006 Nov;64(10):356-63 [17122451.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):719-20 [11127406.001]
  • (PMID = 19816666.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


57. Zhang H, Saeki K, Kimura A, Saeki K, Nakahara M, Doshi M, Kondo Y, Nakano T, Yuo A: Efficient and repetitive production of hematopoietic and endothelial cells from feeder-free monolayer culture system of primate embryonic stem cells. Biol Reprod; 2006 Feb;74(2):295-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have established an innovative culture system for the efficient differentiation of hematopoietic and endothelial cells from primate embryonic stem (ES) cells without feeder cells, embryoid bodies, or cell-sorting processes.
  • These finger-like cells were positive for mesodermal and/or hemangioblastic markers of kinase insert domain receptor (KDR) and T-cell acute lymphocytic leukemia 1 (TAL1), and produced large amounts of protein tyrosine phosphatase, receptor type, C-positive hematopoietic cells.
  • These hematopoietic cells showed the morphology of immature hematopoietic cells, formed blast cell colonies with high efficiency, and were positive for CD34 antigen, KDR, TAL1, and GATA binding protein 1, suggesting that these blast cells are equivalent to the multipotent hematopoietic progenitor cells.
  • [MeSH-major] Cell Culture Techniques. Macaca fascicularis / embryology. Stem Cells / cytology
  • [MeSH-minor] Animals. Antigens, CD34 / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers / metabolism. Cell Differentiation. Endothelial Cells / cytology. Endothelial Cells / physiology. Erythropoietin / pharmacology. GATA1 Transcription Factor / metabolism. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / physiology. Macrophages / cytology. Macrophages / physiology. Mice. Proto-Oncogene Proteins / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Zebrafish Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Biol Reprod. 2006 Sep;75(3):487 [16625002.001]
  • (PMID = 16221992.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers; 0 / GATA1 Transcription Factor; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 0 / Zebrafish Proteins; 0 / gata1 protein, zebrafish; 11096-26-7 / Erythropoietin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


58. Liu J, Zhang LQ, Hu Q, Lin HH, Liu AG, Tao HF, Song YQ, Zhang XL: [Expression of Daxx in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb;9(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Daxx in children with acute leukemia].
  • OBJECTIVE: To investigate Daxx expression and its clinical significance in children with acute leukemia.
  • METHODS: The expression of Daxx protein was detected by immunohistochemical assay in 50 children with newly diagnosed acute leukemia (34 cases of acute lymphocytic leukemia and 16 cases of acute non-lymphocytic leukemia).
  • RESULTS: Daxx protein was expressed in 38.0% of 50 children with acute leukemia, which was significantly higher than that of the control group (5.0%) (P < 0.05).
  • The children with acute non-lymphocytic leukemia had significantly higher Daxx expression levels (62.5%) than those with acute lymphocytic leukemia (26.5%; P < 0.05) as well as the control group (P < 0.05).
  • There were no significant differences in the Daxx expression between acute lymphocytic leukemia children and the control group.
  • Daxx protein was expressed in 55.6% of high risk group of acute lymphocytic leukemia but it was not expressed in standard risk group of acute lymphocytic leukemia (P < 0.05).
  • CONCLUSIONS: Daxx expression is abnormal in children with acute leukemia and associated with some clinical features of acute leukemia, suggesting that it may play an important role in the genesis and development of acute leukemia.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Leukemia, Myeloid, Acute / metabolism. Nuclear Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306074.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DAXX protein, human; 0 / NF-kappa B; 0 / Nuclear Proteins
  •  go-up   go-down


59. Giralt S: The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol; 2006 Apr;33(2 Suppl 5):S36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonmyeloablative stem cell transplants provide a viable therapeutic option for older patients or patients with comorbid conditions, who were previously deemed to be ineligible for transplantation.
  • Despite improvements in clinical outcomes, graft-versus-host disease (GVHD) remains a significant and potentially lethal complication.
  • Alemtuzumab is a humanized monoclonal antibody that targets the CD52 antigen, which is highly expressed on both B and T lymphocytes.
  • By depleting T cells in both the donor and the recipient, alemtuzumab has been shown to prevent development of both acute and chronic GVHD, without inhibiting the benefits associated with the graft-versus-leukemia effect.
  • Clinical trials have shown that alemtuzumab is able to decrease the incidence of acute and chronic GVHD without impairing engraftment.
  • Furthermore, in chronic lymphocytic leukemia therapy, alemtuzumab has been shown to purge malignant cells from the host to allow for harvesting for the purpose of autologous transplantation.
  • Greater insight into alemtuzumab's pharmacokinetic activity would assist in developing a schedule that can optimize alemtuzumab-mediated T-cell depletion to prevent GVHD, while retaining sufficient host T-cell activity to encourage the graft-versus-leukemia effect and prevent relapse.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphocyte Depletion. T-Lymphocytes / drug effects. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720202.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 33
  •  go-up   go-down


60. Wu BY, Guo KY, Song CY, Wu LX, Yang YL, Li YH, Xiao LL: [The outcomes of the thirty patients with refractory leukemia treated with related HLA haploidentical stem cells transplantation]. Zhonghua Nei Ke Za Zhi; 2006 Feb;45(2):130-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The outcomes of the thirty patients with refractory leukemia treated with related HLA haploidentical stem cells transplantation].
  • OBJECTIVE: To assess the outcomes of the therapy for patients with refractory leukemia with HLA haploidentical stem cells transplantation.
  • METHODS: To analyze the outcomes of 30 patients with refractory leukemia who underwent HLA haploidentical peripheral blood stem cells transplantation from August 1998 to August 2004.
  • RESULTS: Thirty refractory leukemia patients including 13 cases of acute non-lymphocytic leukemia, 10 cases of acute lymphocytic leukemia (ALL), 6 cases of chronic myeloid leukemia and 1 case of phase IV non-Hodgkin's lymphoma underwent HLA haploidentical peripheral blood stem cells transplantation.
  • Twenty-seven patients were successfully grafted, one failed to graft, one died from severe fungal infection at day 2 and one died from severe veno-occlusive disease at day 28.
  • The mean time of white cell count more than 1.0 x 10(9)/L was 14 (11-18) days and platelet count more than 20 x 10(9)/L was 15 (11-18) days.
  • Severe acute graft versus host disease occurred in six patients and four of them died.
  • Seven patients suffered from chronic graft versus host disease.
  • Fourteen patients are still surviving, and ten have disease free survival.
  • CONCLUSION: It is concluded from our observation that HLA haploidentical peripheral blood stem cells transplantation may be an effective therapy for refractory and relapse leukemia.
  • Some patients with refractory and relapse leukemia treated with HLA haploidentical stem cells transplantation may have disease free survival.
  • Graft versus leukemia effect may be strong in patients receiving HLA haploidentical blood stem cells transplantation and leukemia will probably be relapsed when the patient without complete remission was treated with this therapy.
  • [MeSH-major] HLA Antigens. Leukemia / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Histocompatibility. Humans. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624123.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


61. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, Toughe GR, Kordmahin M, Khoshnoodi J, Roohi A, Tavoosi N, Mellstedt H, Rabbani H, Shokri F: Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol; 2007;28(6):318-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia.
  • Overexpression of Ror1 has recently been reported in B-cell chronic lymphocytic leukemia.
  • The aim of this study was to explore the expression profile of Ror1 in acute lymphoblastic leukemia (ALL) cells.
  • A similar expression pattern was observed in ALL cell lines, with 4 of 12 (33%) being positive.
  • In conclusion, our findings propose Ror1 as a new tumor-associated antigen and a potential tool for targeted immunotherapy and monitoring of minimal residual disease in ALL.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Receptor Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Blood Cells / enzymology. Bone Marrow / enzymology. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Iran. Male. Neoplasm, Residual / diagnosis. Neoplasm, Residual / enzymology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor Tyrosine Kinase-like Orphan Receptors. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [ErratumIn] Tumour Biol. 2008;29(2):136. Omran, Hossein Asgarian [corrected to Asgarian-Omran, Hossein]
  • (PMID = 18354269.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  •  go-up   go-down


62. Delabesse E, Ogilvy S, Chapman MA, Piltz SG, Gottgens B, Green AR: Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. Mol Cell Biol; 2005 Jun;25(12):5215-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stem cell leukemia (SCL) gene, also known as TAL-1, encodes a basic helix-loop-helix protein that is essential for the formation of all hematopoietic lineages, including primitive erythropoiesis.
  • Here, we have quantitated transcripts from SCL and neighboring genes in multiple hematopoietic cell types.
  • A systematic survey of histone H3 and H4 acetylation throughout the SCL locus in different hematopoietic cell types identified several peaks of histone acetylation between SIL and MAP17, all of which corresponded to previously characterized SCL enhancers or to the MAP17 promoter.
  • This +40 region is conserved in human-dog-mouse-rat sequence comparisons, functions as an erythroid cell-restricted enhancer in vitro, and directs beta-galactosidase expression to primitive, but not definitive, erythroblasts in transgenic mice.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2003;4(2):P1 [12620117.001]
  • [Cites] Genomics. 2003 Mar;81(3):249-59 [12659809.001]
  • [Cites] Cell. 2003 May 2;113(3):405-17 [12732147.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1870-83 [14966269.001]
  • [Cites] Blood. 2004 May 1;103(9):3342-8 [14726374.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4078-83 [14764531.001]
  • [Cites] Blood. 2004 Jul 1;104(1):19-25 [15031208.001]
  • [Cites] J Biol. 2002;1(1):5 [12144710.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):675-81 [5768863.001]
  • [Cites] J Immunol. 1973 Jun;110(6):1470-5 [4541304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1863-7 [1057176.001]
  • [Cites] Gan. 1982 Aug;73(4):600-5 [6983990.001]
  • [Cites] Development. 1999 Nov;126(22):5073-84 [10529424.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3754-63 [10572089.001]
  • [Cites] J Hematother Stem Cell Res. 1999 Aug;8(4):335-42 [10634171.001]
  • [Cites] Nat Biotechnol. 2000 Feb;18(2):181-6 [10657125.001]
  • [Cites] Development. 2000 May;127(9):1931-41 [10751181.001]
  • [Cites] Development. 2000 Jun;127(11):2447-59 [10804185.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):375-80 [10951271.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14494-9 [11121052.001]
  • [Cites] Genome Res. 2001 Jan;11(1):87-97 [11156618.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6747-52 [11381108.001]
  • [Cites] Development. 2001 Dec;128(23):4815-27 [11731461.001]
  • [Cites] Genome Res. 2002 May;12(5):749-59 [11997341.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3931-8 [12010791.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1502-14 [7632958.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Cell. 1996 Jul 12;86(1):47-57 [8689686.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):493-500 [8701988.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3713-21 [8670875.001]
  • [Cites] Genomics. 1995 Dec 10;30(3):506-13 [8825637.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4123-9 [8861941.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 1;24(21):4158-64 [8932366.001]
  • [Cites] Development. 1996 Dec;122(12):3991-9 [9012519.001]
  • [Cites] Development. 1997 Jan;124(2):537-47 [9053329.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1607-14 [9032288.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):488-93 [9087406.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4487-92 [9114016.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4400-7 [9336475.001]
  • [Cites] Cell Growth Differ. 1997 Nov;8(11):1171-9 [9372240.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2419-28 [9395238.001]
  • [Cites] Blood. 1998 Jan 15;91(2):419-30 [9427694.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):473-9 [9472016.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):4029-45 [9670018.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):128-42 [10208748.001]
  • [Cites] Blood. 1999 May 1;93(9):2760-70 [10216069.001]
  • [Cites] Development. 1999 Jun;126(12):2799-811 [10331989.001]
  • [Cites] Leukemia. 1999 May;13(5):750-9 [10374880.001]
  • [Cites] Development. 1999 Sep;126(17):3891-904 [10433917.001]
  • [Cites] Genes Cells. 2002 Dec;7(12):1243-54 [12485164.001]
  • [Cites] Toxicol Lett. 2003 Jan 31;137(1-2):85-93 [12505434.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4547-53 [12036887.001]
  • [Cites] EMBO J. 2002 Jun 17;21(12):3039-50 [12065417.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):975-9 [12214599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15468-73 [12438646.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):582-6 [12466854.001]
  • [Cites] EMBO J. 2002 Dec 16;21(24):6700-8 [12485991.001]
  • [Cites] Cell. 1983 Oct;34(3):717-26 [6605197.001]
  • [Cites] J Virol. 1985 Jul;55(1):23-33 [4009794.001]
  • [Cites] Leuk Res. 1985;9(7):921-6 [3860700.001]
  • [Cites] J Exp Med. 1985 Nov 1;162(5):1561-78 [4056659.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):531-8 [3093393.001]
  • [Cites] Blood. 1988 Dec;72(6):1968-77 [3196874.001]
  • [Cites] Blood. 1990 Mar 15;75(6):1252-61 [2310825.001]
  • [Cites] Hum Cell. 1989 Dec;2(4):423-9 [2486667.001]
  • [Cites] Cell. 1991 May 17;65(4):677-89 [1709592.001]
  • [Cites] Oncogene. 1992 Apr;7(4):653-60 [1565464.001]
  • [Cites] Blood Rev. 1992 Jun;6(2):118-24 [1633508.001]
  • [Cites] J Clin Invest. 1992 Aug;90(2):429-38 [1322939.001]
  • [Cites] Exp Hematol. 1993 Feb;21(2):289-98 [7678813.001]
  • [Cites] Nature. 1994 Sep 15;371(6494):221-6 [8078582.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1184-97 [7926723.001]
  • [Cites] Leuk Lymphoma. 1995 Feb;16(5-6):493-503 [7787756.001]
  • (PMID = 15923636.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Histones; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / PDZK1IP1 protein, human; 0 / Pdzk1ip1 protein, mouse; 0 / Pdzk1ip1 protein, rat; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 135471-20-4 / TAL1 protein, human
  • [Other-IDs] NLM/ PMC1140604
  •  go-up   go-down


63. Turner BC, Eves T, Refaeli Y: Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma. DNA Cell Biol; 2008 Mar;27(3):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
  • There has been great interest in a novel set of agents that are able to mimic the function of the BH3 domain by binding to the groove of Bcl-2-like proteins and initiating the cell death sequence.
  • We sought to examine the efficacy of BH3 mimetics in a spontaneous mouse model of B-cell neoplasia.
  • We report here that two BH3 mimetics (HA-14-1 and BH3-I-2') were able to induce apoptosis of murine B-cell lymphoma cells in vitro and in vivo.
  • Decreased expression of either Bim or Puma from B-cell tumor cells was able to protect these cells from the apoptosis induced by these BH3 mimetics, suggesting that they function through other means.
  • We conclude that while the BH3-mimetic drugs are effective at inducing cell death of lymphoma cells in vitro and in vivo, their unclear molecular specificity and their ability to kill normal cells may limit their therapeutic uses in humans.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Tumor Burden / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Apoptosis Regulatory Proteins / genetics. Biomimetics. Cell Line, Tumor. Cell Proliferation. Disease Models, Animal. Female. Humans. Membrane Proteins / genetics. Mice. Mice, Inbred C57BL. Molecular Weight. Protein Structure, Tertiary / physiology. Proto-Oncogene Proteins / genetics. Remission Induction. Treatment Outcome. Tumor Suppressor Proteins / genetics. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163880.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-11802
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Membrane Proteins; 0 / PUMA protein, mouse; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


64. Hurren R, Beheshti Zavareh R, Dalili S, Wood T, Rose D, Chang H, Jamal N, Messner H, Batey RA, Schimmer AD: A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death. Apoptosis; 2008 Jun;13(6):748-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death.
  • Q(2 )induced cell death in leukemia, myeloma, and solid tumor cell lines with LD50s in the low to submicromolar range.
  • Moreover, Q(2) induced cell death in primary acute myeloid leukemia (AML) cells preferentially over normal hematopoietic cells.
  • In a mouse model of leukemia, Q(2) delayed tumor growth.
  • Mechanistically, Q(2) induced cell death through caspase independent mechanisms.
  • Potentially consistent with the induction of autophagic cell death, Q(2) treatment led to a punctate distribution of LC3 and increased MDC staining.
  • Thus, Q(2) is a novel quinolinium with preclinical activity in malignancies such as leukemia and myeloma and warrants further investigation.
  • [MeSH-major] Cell Death / drug effects. Quinolinium Compounds / pharmacology
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Animals. Autophagy / drug effects. Caspases / physiology. Cell Line, Tumor. Cell Survival / drug effects. HeLa Cells. Humans. Jurkat Cells. Lethal Dose 50. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Mice. Mice, Inbred DBA. Tumor Cells, Cultured. U937 Cells

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415680.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-methyl-2-(3-(1-methyl-1,2-dihydroquinolin-2-yliden)prop-1-enyl)quinolinium iodide; 0 / Amino Acid Chloromethyl Ketones; 0 / Quinolinium Compounds; 0 / benzyloxycarbonyltyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone; EC 3.4.22.- / Caspases
  •  go-up   go-down


65. Luo SD, Wu Y, Chen JH, Liu HK, Chen YZ: [Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug;16(4):742-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia].
  • This study was aimed to investigate the gene expression profile of TGF-beta signal transduction pathway in B-cell type acute lymphocytic leukemia (B-ALL).
  • The gene expression profiles in B-ALL primary cells and cell lines (NALM6 cells, Raji cells), B-lymphocyte of control were detected by cDNA microarray including 113 different genes in human TGF-beta/BMP signal transduction pathway, and TGF-beta(1) mRNA expression was detected by real time RT-PCR.
  • The B lymphocytes in peripheral blood of heacthy persons sorted by flow cytometry were used as control.
  • The results showed that as compared with B lymphocytes in peripheral blood of heacthy persons, the TGF-beta(1) expression in B-ALL cells, NALM6 cells and Raji cells were down-regulationed, myc and smad1 gene expressions were up-regulated, IL-6, smad 7 gene expressions were down-regulated.
  • It is concluded that TGF-beta signal transduction is abnormal in B-cell type acute lymphocytic leukemia.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18718051.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


66. Nurzyńska-Flak J, Kowalczyk JR: [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000]. Wiad Lek; 2005;58(5-6):284-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000].
  • Purpose of the work was the analysis of the number and structure of leukemia in children living in the Lublin Region of Poland.
  • Among leukemias, according to the International Classification of Childhood Cancers, were counted: lymphoid leukemia, acute non-lymphocytic leukemia, chronic myeloid leukemia, other specified and unspecified leukemias.
  • Number of cases and incidence for the whole group as well as sex, age and descending (rural and urban) distribution of leukemias were calculated.
  • RESULTS: 244 cases of leukemia were reported (152 boys--62.3% and 92 girls--37.7%).
  • CONCLUSIONS: In the Lublin Region lower percentage of leukemia was observed compared to the values determined for the country.
  • Incidence of leukemia was falling, but the analysis in age-groups proved, that it was caused by the decreasing incidence in children under 5 year.
  • [MeSH-major] Leukemia / epidemiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238118.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


67. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood; 2006 Aug 15;108(4):1421-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
  • Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain.
  • Outcome of patients with such mutations after allogeneic stem cell transplantation (Allo-SCT) is unknown.
  • Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL).
  • Disease response was complete molecular (CMR; n = 7), major molecular (n = 2), and no response (n = 1).
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Point Mutation. Stem Cell Transplantation
  • [MeSH-minor] Adult. Benzamides. Blast Crisis / genetics. Blast Crisis / metabolism. Blast Crisis / mortality. Blast Crisis / therapy. Disease-Free Survival. Female. Graft Survival / drug effects. Graft Survival / genetics. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Homologous. Treatment Outcome


68. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene; 2007 May 28;26(25):3644-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
  • CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets.
  • In 2001, alemtuzumab was approved for marketing in the United States and Europe for use in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
  • Alemtuzumab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual disease, in preparation for stem cell transplantation and to prevent acute and chronic graft versus host disease.
  • Alemtuzumab is frequently associated with acute 'first-dose' reactions when administered intravenously, but is much better tolerated when administered subcutaneously without loss of therapeutic efficacy.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / therapeutic use. Immunotherapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530018.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 75
  •  go-up   go-down


69. Huang Z, Chai YH, Cen JN, He HL, Li J: [Expression of CYP3A5 mRNA in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul;11(7):549-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CYP3A5 mRNA in children with acute leukemia].
  • So far the studies on CYP3A5 gene has only been focused on the leukemia cell lines.
  • This study examined the polymorphism of CYP3A5 and tried to find the possible relationship between CYP3A5 gene expression and treatment outcome or prognosis in children with acute leukemia.
  • METHODS: The genotype distribution of CYP3A5-6986A/G gene polymorphism was detected with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 66 children with newly diagnosed acute leukemia (AL) and 22 control individuals.
  • In patients with acute lymphocytic leukaemia (ALL), the complete remission (CR) rate in the group with a low expression of wt-CYP3A5 mRNA was significantly higher than that in the group with a high expression (p<0.05).
  • The expression increased before ALL relapse compared with that in CR in a patient, while in the other patient, the expression was kept in a low level and the patient remained in CR CONCLUSIONS: wt-CYP3A5 mRNA expression was associated with the treatment outcome and prognosis in children with AL.
  • Dynamic monitoring for wt-CYP3A5 mRNA expression in the bone marrow may be useful in the evaluation of the disease severity in childhood acute leukemia.
  • [MeSH-major] Cytochrome P-450 CYP3A / genetics. Leukemia / enzymology. RNA, Messenger / analysis
  • [MeSH-minor] Acute Disease. Child. Genotype. Humans. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650988.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


70. Zhang W, Dai BT, Xu YH: [Effects of matrine on invasion and metastasis of leukemia cell line Jurkat]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Oct;28(10):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of matrine on invasion and metastasis of leukemia cell line Jurkat].
  • OBJECTIVE: To study the inhibitory effects of matrine, in different concentrations, on invasion and metastasis of human acute lymphocytic leukemia cell line Jurkat.
  • Then cell adhesion assay, cell migration assay and matrigel invasion assay were used respectively to observe the effects of matrine on adhesion, migration and invasive capacity of Jurkat cells.
  • RESULTS: As compared with the control group, the adhesion of Jurkat to fibronectin (FN) was significantly inhibited by 0.15 g/L and 0.2 g/L of matrine (P < 0.05); the cell migration and invasive capacity were significantly lowered by 0.1 g/L, 0.15 g/L and 0.2 g/L matrine (P < 0.01).
  • CONCLUSIONS: Matrine is a good drug for antagonizing the invasion and metastasis of leukemia cells, it may roundly inhibit the adhesion, migration and invasive capacity of Jurkat cells, the mechanism might be related with the down-regulation of MMP-9 mRNA expression.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123329.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Drugs, Chinese Herbal; 0 / Quinolizines; 519-02-8 / matrine
  •  go-up   go-down


71. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol; 2010 Jan 1;84(1):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MicroRNAs are small non-coding RNAs that act at the post-transcriptional level, regulating protein expression by repressing translation or destabilizing mRNA target.
  • Because of their discovery, microRNAs have been associated with almost every normal cell function, including proliferation, differentiation and apoptosis.
  • Several lines of evidence suggest that they have an important role in normal hematopoiesis as exemplified by the role of mir-155 and mir-150 in the differentiation of B and T lymphocytes, the suppressive role of mir-221 and mir-222 in erythroid differentiation, the inhibitory effect of mir-181 on hematopoietic differentiation and the induction of myeloid differentiation by mir-223.
  • Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. Down-Regulation. Erythroid Precursor Cells / cytology. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor. Humans. Invertebrates / genetics. Lymphocytes / cytology. Mice. Myeloid Cells / cytology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oncogenes. RNA, Neoplasm / antagonists & inhibitors. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744129.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Number-of-references] 110
  •  go-up   go-down


72. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W: Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother; 2008 Feb;57(2):233-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigated the pro-apoptotic potential of a novel TRAIL fusion protein designated scFvCD19:sTRAIL, consisting of a CD19-specific single-chain Fv antibody fragment (scFv) fused to the soluble extracellular domain of TRAIL (sTRAIL).
  • Potent apoptosis was induced by scFvCD19:sTRAIL in several CD19-positive tumor cell lines, whereas normal blood cells remained unaffected.
  • Simultaneous treatment of CD19-positive cell lines with scFvCD19:sTRAIL and valproic acid (VPA) or Cyclosporin A induced strongly synergistic apoptosis.
  • Treatment of patient-derived acute B-lymphoblastic leukemia (B-ALL) and chronic B-lymphocytic leukemia (B-CLL) cells resulted in strong tumoricidal activity that was further enhanced by combination with VPA.
  • [MeSH-major] Antigens, CD19. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Leukemia, B-Cell / drug therapy. Recombinant Fusion Proteins / pharmacology. TNF-Related Apoptosis-Inducing Ligand

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665197.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antineoplastic Agents; 0 / Immunoglobulin Fragments; 0 / Recombinant Fusion Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 614OI1Z5WI / Valproic Acid; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


73. Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D: Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol; 2005 Aug;78(2):359-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
  • The major histocompatibility complex nonrestricted cytotoxic leukemic T cell line T acute lymphoblastic leukemia (TALL)-104 is being pursued as a therapeutic agent for cancer.
  • Here, we examined the roles played by natural cytotoxicity receptors (NCR), killer cell immunoglobulin-like receptors, cytolytic granule components, and tumor necrosis factor (TNF) family members in tumor recognition and lysis by TALL-104 cells.
  • Although negative for the NCR natural killer (NK)p44, this cell line was found to express NKp46.
  • The data demonstrate the ability of TALL-104 cells to recognize a wide variety of tumors with NK cell receptors and kill them with a broad arsenal of cytolytic effector mechanisms, including cytolytic granules and TNF family ligands.
  • [MeSH-major] Cytotoxicity, Immunologic / immunology. Killer Cells, Natural / immunology. Lymphocyte Activation / immunology. Signal Transduction / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adoptive Transfer. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD / immunology. Antigens, CD3 / immunology. Apoptosis Regulatory Proteins. Carcinogens / pharmacology. Cell Degranulation / immunology. Fas Ligand Protein. Histocompatibility Antigens Class I / immunology. Humans. Immediate-Early Proteins / immunology. Ionomycin / pharmacology. Ionophores / pharmacology. Jurkat Cells. Membrane Glycoproteins / immunology. Monomeric GTP-Binding Proteins / immunology. NK Cell Lectin-Like Receptor Subfamily C. NK Cell Lectin-Like Receptor Subfamily K. Natural Cytotoxicity Triggering Receptor 1. Neoplasms / immunology. Neoplasms / therapy. Receptors, Immunologic / immunology. Receptors, KIR. Receptors, KIR3DL2. Receptors, Natural Killer Cell. TNF-Related Apoptosis-Inducing Ligand. Tetradecanoylphorbol Acetate / pharmacology. Tumor Necrosis Factor-alpha / immunology. Tumor Necrosis Factors / immunology. U937 Cells

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937142.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01 CA20833; United States / NCI NIH HHS / CA / CA83859
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Apoptosis Regulatory Proteins; 0 / CD244 protein, human; 0 / Carcinogens; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Histocompatibility Antigens Class I; 0 / Immediate-Early Proteins; 0 / Ionophores; 0 / KIR3DL2 protein, human; 0 / KLRC1 protein, human; 0 / KLRK1 protein, human; 0 / Membrane Glycoproteins; 0 / NCR1 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily C; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Natural Cytotoxicity Triggering Receptor 1; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DL2; 0 / Receptors, Natural Killer Cell; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Necrosis Factors; 56092-81-0 / Ionomycin; EC 3.6.5.2 / GEM protein, human; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


74. Wang YX, Zhang JH, Gu ZW: [Wnt/beta-catenin signal pathway and malignant hematological disease -- review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):234-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Wnt/beta-catenin signal pathway and malignant hematological disease -- review].
  • This article reviews the newest studies on relationship between Wnt/beta-catenin signal pathway and hematological malignancies (multiple myeloma, chronic myeloid leukemia, chronic lymphocytic leukemia, acute leukemia and so on) in order to reveal the related pathogenesis of hematological malignancies and provide new opinions for target therapy of these diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236787.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


75. Khan G: High incidence of Epstein-Barr virus infection in childhood acute lymphocytic leukemia. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):890-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Epstein-Barr virus infection in childhood acute lymphocytic leukemia.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):63-7 [20090225.001]
  • (PMID = 21045472.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] India
  •  go-up   go-down


76. Chumak AA, Abramenko IV, Bilous NI, Filonenko IA, Kostin OV, Pleskach OY, Pleskach GV, Efremova N, Yanko J: Persistent infections and their relationship with selected oncologic and non-tumor pathologies. J Immunotoxicol; 2010 Oct-Dec;7(4):279-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the study here, we analyzed HCV (as well as cytomegalovirus [CMV]) prevalence among Chernobyl nuclear power plant (NPP) accident sufferers--cleanup workers, local residents, NPP workers, and convalescent patients--who suffered acute radiation syndrome (ARS) as a result of the 1986 accident, and individuals who had not been exposed to ionizing radiation (IR).
  • We also investigated, due to a high incidence of chronic lymphocytic leukemia (CLL) among Chernobyl sufferers, if there was homology between immunoglobulins (Igs) generated by these transformed cells and known antiviral and antimicrobial Igs.
  • [MeSH-major] Acute Radiation Syndrome / epidemiology. Cytomegalovirus / immunology. Cytomegalovirus Infections / epidemiology. Hepacivirus / immunology. Hepatitis C, Chronic / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518708.001).
  • [ISSN] 1547-6901
  • [Journal-full-title] Journal of immunotoxicology
  • [ISO-abbreviation] J Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Neoplasm; 0 / Antigens, Viral
  •  go-up   go-down


77. Clark BR, Ferketich AK, Fisher JL, Ruymann FB, Harris RE, Wilkins JR 3rd: Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio. Pediatr Blood Cancer; 2007 Nov;49(6):797-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio.
  • BACKGROUND: This ecologic study examined the geographic distribution of childhood leukemias in Ohio, 1996-2000, among children aged 0-19 for evidence that population mixing may be a factor.
  • RESULTS: Of the 585 cases, 73.3% were acute lymphocytic leukemia (ALL), 16.6% acute myelogenous leukemia (AML), 3.2% acute monocytic leukemia (AMoL), and 2.6% chronic myelogenous leukemia (CML).
  • Rates for total leukemia burden were significantly below national levels for all races (P = 0.00001), likely due to poor ascertainment of cases.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Population Density. Population Dynamics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Rural Population. Urban Population


78. Zhang YL, Ren JH, Guo XN, Zhang JN, Wang Y, Qiao SK, Lin FR: [Expression of c-fes gene in leukemia cells and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1429-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-fes gene in leukemia cells and its clinical significance].
  • This study was purposed to investigate the expression of c-fes gene in leukemia patients and its clinical significance.
  • The expression of c-fes mRNA in bone marrow cells from 121 cases of acute and chronic leukemia patients, and the expression of c-fes mRNA in peripheral blood mononuclear cells of 20 normal persons were detected by real time-quantitative reverse transcription polymerase chain reaction (RQ-PCR).
  • The results showed that the level of c-fes mRNA in AML patients was higher than that in normal controls [(48.017 +/- 57.170) x 10(-3) vs (0.152 +/- 0.398) x 10(-3)] (p < 0.0001); but there was no significant differences of level of c-fes mRNA between samples of ALL and normal controls(0.047 +/- 0.068) x 10(-3) vs(0.152 +/- 0.398) x 10(-3) (p>0.05); the level of c-fes mRNA in CML patients was higher than that in normal persons (21.605 +/- 24.818) x 10(-3) vs (0.152 +/- 0.398) x 10(-3) (p < 0.0001).
  • The positive expression rate of c-fes gene in CML-CP patients (80%) was higher than that in CML-AP patients (66.7%) and CML-BP (28.6%) patients.
  • The remission rate of AML (except M(3))patients who had expression of c-fes gene was 81.08%, which was higher than that of patients with no expression of c-fes gene (40.00%).
  • It is concluded that c-fes gene expression was found in myeloid leukemias, whereas low or no expression in lymphocytic leukemias.
  • All AML (except M(3))patients with high level of c-fes mRNA may get good prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030920.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / FES protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fes
  •  go-up   go-down


79. Kassouf MT, Hughes JR, Taylor S, McGowan SJ, Soneji S, Green AL, Vyas P, Porcher C: Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells. Genome Res; 2010 Aug;20(8):1064-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that TAL1 coordinates expression of genes in most known red cell-specific processes.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1999 Jun;126(12):2799-811 [10331989.001]
  • [Cites] Genome Res. 2009 Dec;19(12):2172-84 [19887574.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5033-8 [12586629.001]
  • [Cites] Mol Cell Biol. 2008 Dec;28(24):7394-401 [18852285.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4678-86 [16514064.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jan;11(1):73-80 [14718926.001]
  • [Cites] Genome Res. 2002 Oct;12(10):1599-610 [12368253.001]
  • [Cites] Cell. 1984 Jul;37(3):721-9 [6234993.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4298-307 [18723693.001]
  • [Cites] J Med Invest. 2008 Feb;55(1-2):9-16 [18319540.001]
  • [Cites] Exp Cell Res. 2005 Oct 1;309(2):410-8 [16081065.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2686-92 [10644730.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3007-14 [17132716.001]
  • [Cites] Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):107-18 [16487043.001]
  • [Cites] Eur J Haematol. 2008 Nov;81(5):399-402 [18778368.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2492-502 [10835348.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3359-70 [16380451.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Dec;34(12):1513-8 [12379271.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1527-37 [10359562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8 [8901585.001]
  • [Cites] Am J Hematol. 2009 Feb;84(2):65-70 [19051264.001]
  • [Cites] Cell. 2008 Mar 21;132(6):958-70 [18358809.001]
  • [Cites] Eur J Cell Biol. 1998 Jan;75(1):66-77 [9523157.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):11-24 [14725896.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10141-6 [19497860.001]
  • [Cites] Gene Expr Patterns. 2007 Jan;7(3):215-26 [17112790.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6681-94 [18779319.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1056-67 [18550854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9751-6 [15210949.001]
  • [Cites] Immunol Rev. 2008 Aug;224:183-200 [18759927.001]
  • [Cites] Acta Biochim Pol. 1996;43(1):227-40 [8790727.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5904-14 [10557077.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8635-42 [18922940.001]
  • [Cites] Blood. 2007 Jan 15;109(2):811-8 [17003376.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2940-50 [9763581.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Dev Biol. 2006 Jun 15;294(2):525-40 [16626682.001]
  • [Cites] Oncogene. 1991 Feb;6(2):187-94 [2000219.001]
  • [Cites] Immunity. 2003 Feb;18(2):217-27 [12594949.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):1256-65 [8289805.001]
  • [Cites] Eur J Biochem. 1995 Jun 1;230(2):760-5 [7607249.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(20):7176-87 [17698584.001]
  • [Cites] Blood Cells Mol Dis. 2006 Mar-Apr;36(2):232-8 [16524748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12560-4 [17636116.001]
  • [Cites] Blood. 2001 Feb 15;97(4):901-10 [11159515.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7585-99 [14560005.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3928-34 [19724054.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3244-52 [17158226.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2662-72 [16332976.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45854-9 [12239222.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Genes Cells. 2003 Sep;8(9):769-77 [12940824.001]
  • [Cites] Exp Hematol. 2007 Mar;35(3):358-67 [17309816.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2277-86 [17690693.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5205-14 [15923635.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29166-74 [18694939.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4958-67 [10490830.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):26-32 [12069807.001]
  • [Cites] Blood. 2005 May 1;105(9):3502-11 [15644413.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38458-65 [15247232.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3808-15 [10207104.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1526-37 [19114560.001]
  • [Cites] J Biol Chem. 2009 May 15;284(20):13291-5 [19182219.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] Blood Rev. 2006 Mar;20(2):93-110 [15961204.001]
  • [Cites] PLoS Genet. 2006 Feb;2(2):e14 [16462943.001]
  • [Cites] Biochem J. 2007 Dec 1;408(2):e5-6 [17990984.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22223-30 [11294862.001]
  • [Cites] Exp Hematol. 1995 Feb;23(2):99-107 [7828675.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):161-72 [19807729.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36665-75 [18854306.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14347-54 [9603943.001]
  • [Cites] Blood. 2005 May 15;105(10):3862-70 [15677567.001]
  • [Cites] Blood. 2002 May 15;99(10):3500-4 [11986200.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):804-9 [19339686.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):905-13 [12867998.001]
  • [Cites] Nat Biotechnol. 2008 Nov;26(11):1293-300 [18978777.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8026-31 [18524950.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1188-90 [15173120.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):429-40 [10611221.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28296-306 [16861236.001]
  • [Cites] Stat Appl Genet Mol Biol. 2004;3:Article3 [16646809.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6792-803 [11118214.001]
  • [Cites] Immunity. 2003 Oct;19(4):621-32 [14563325.001]
  • [Cites] J Clin Invest. 1999 Feb;103(3):331-40 [9927493.001]
  • [Cites] Cell. 1996 Sep 20;86(6):917-27 [8808627.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1315-27 [9178892.001]
  • [Cites] Cell. 1994 Jul 15;78(1):45-57 [8033210.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10226-31 [11517325.001]
  • [Cites] Curr Top Dev Biol. 2008;82:23-53 [18282516.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3352-62 [19179303.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 Oct;33(10):968-79 [17002676.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1908-16 [17053063.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2611-7 [17105810.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30055-62 [15975931.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1198-207 [16627753.001]
  • [Cites] Int J Hematol. 2001 Jun;73(4):463-8 [11503960.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4124-35 [17142833.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2404-10 [10090952.001]
  • [Cites] EMBO J. 2006 Jan 25;25(2):357-66 [16407974.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3651-64 [11439328.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):682-95 [19941827.001]
  • [Cites] Mol Cell Biol. 2009 Oct;29(20):5399-412 [19687298.001]
  • [Cites] Development. 2004 Feb;131(3):693-702 [14729577.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1994;2:28-36 [7584402.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4075-80 [18250229.001]
  • [Cites] Genes Dev. 2010 Feb 1;24(3):277-89 [20123907.001]
  • [Cites] Hematol J. 2000;1(4):235-42 [11920196.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2133-44 [17671650.001]
  • [Cites] Blood. 2007 Aug 1;110(3):894-901 [17412890.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Blood. 2009 May 28;113(22):5456-65 [19346495.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2064-71 [16690966.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1652-5 [10688820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):112-24 [9887104.001]
  • [Cites] Blood. 2005 May 15;105(10):3871-4 [15677556.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W199-203 [15215380.001]
  • [Cites] Cell. 1995 Oct 6;83(1):59-67 [7553874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2430-40 [12239153.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 24;1372(1):91-101 [9651491.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2248-56 [16763211.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 19;312(3):780-6 [14680833.001]
  • [Cites] Biochem J. 2009 Jun 1;420(2):133-54 [19426143.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2191-201 [19011221.001]
  • [Cites] Nucleic Acids Res. 2009 Nov;37(21):7024-38 [19767611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6637-42 [12011427.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1390-402 [12556498.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(20):7206-19 [17709394.001]
  • [Cites] Am J Med Sci. 1999 Oct;318(4):241-56 [10522552.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3939-48 [18988878.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):667-81 [19941826.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] EMBO J. 2005 Nov 2;24(21):3712-23 [16222338.001]
  • [Cites] Bioinformatics. 2009 Jul 15;25(14):1754-60 [19451168.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6355-62 [16024775.001]
  • [Cites] Nat Genet. 2003 May;34(1):59-64 [12669066.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):281-91 [10983976.001]
  • [Cites] Development. 2006 Dec;133(24):4913-23 [17108004.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(23):10235-50 [16287841.001]
  • [Cites] Blood. 2007 Jul 15;110(2):509-18 [17403918.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1597-608 [10102630.001]
  • [Cites] Cell Res. 2008 Aug;18(8):834-45 [18560381.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):337-45 [10721728.001]
  • [Cites] Immunity. 1996 Dec;5(6):537-49 [8986714.001]
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):399-406 [10878804.001]
  • [Cites] Development. 1999 Oct;126(20):4603-15 [10498694.001]
  • [Cites] Cell. 1996 Jul 12;86(1):47-57 [8689686.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5390-9 [18349318.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):154-64 [8566749.001]
  • [Cites] Cell Stem Cell. 2009 Feb 6;4(2):180-6 [19200805.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6282-9 [10562540.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] Blood. 1997 Jan 1;89(1):1-25 [8978272.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3261-73 [11719363.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4223-8 [12920035.001]
  • [Cites] Eur J Biochem. 2003 Nov;270(22):4515-22 [14622280.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):191-5 [18391783.001]
  • [Cites] Am J Hematol. 2009 Jun;84(6):354-61 [19425068.001]
  • [Cites] Cell Death Differ. 2004 Dec;11(12):1299-308 [15332117.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7591-6 [10713066.001]
  • (PMID = 20566737.001).
  • [ISSN] 1549-5469
  • [Journal-full-title] Genome research
  • [ISO-abbreviation] Genome Res.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE18720/ GSE21877
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137961146; United Kingdom / Medical Research Council / / MC/ UU/ 12009/15; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse
  • [Other-IDs] NLM/ PMC2909570
  •  go-up   go-down


80. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L: Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, active and tolerable treatments for patients with relapsed or refractory disease are needed.
  • Bendamustine, a mechlorethamine alkylator with novel mechanisms of action, is approved in the United States for rituximab-refractory indolent B-cell NHL.
  • Histologies included follicular (68%), small lymphocytic (20%), marginal zone (11%), and lymphoplasmacytic (1%) lymphoma.
  • Second malignancies occurred in 9 patients (5.6%; 5 myelodysplastic syndromes, 2 acute myelogenous leukemia, 1 chronic myelomonocytic leukemia, and 1 squamous cell carcinoma).
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Drug Resistance, Neoplasm / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Nitrogen Mustard Compounds / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189660.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


81. Aragon-Ching JB, Zujewski JA: CNS metastasis: an old problem in a new guise. Clin Cancer Res; 2007 Mar 15;13(6):1644-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases are increasing, due to the aging population, detection of subclinical disease, and control of systemic disease.
  • In pediatric acute lymphocytic leukemia event-free survival rates are >80% and the CNS is an important source of extramedullary relapse.
  • (d) and the evolving role of radiotherapy in CNS disease and strategies to improve the therapeutic index.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363516.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


82. Hindo H, Buescher ES, Frank LM, Pettit D, Dory C, Byrd R: West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission. J Pediatr Hematol Oncol; 2005 Dec;27(12):659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
  • The authors describe an adolescent with acute lymphocytic leukemia and WNV encephalitis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. West Nile Fever / complications

  • Genetic Alliance. consumer health - West nile virus.
  • MedlinePlus Health Information. consumer health - West Nile Virus.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344671.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antiviral Agents; 0 / Immunoglobulins, Intravenous; 5J49Q6B70F / Vincristine; 6Q205EH1VU / Vancomycin; 75J73V1629 / Ceftriaxone; 9M416Z9QNR / Ceftazidime; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  •  go-up   go-down


83. Lécuyer E, Larivière S, Sincennes MC, Haman A, Lahlil R, Todorova M, Tremblay M, Wilkes BC, Hoang T: Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction. J Biol Chem; 2007 Nov 16;282(46):33649-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This interaction likely provides a rate-limiting step in the transcriptional control of hematopoiesis and leukemia, and similar mechanisms may operate to control the assembly of diverse protein modules.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Amino Acid Sequence. Animals. Cell Differentiation. Humans. LIM Domain Proteins. Megakaryocytes / metabolism. Mice. Models, Molecular. Molecular Conformation. Molecular Sequence Data. NIH 3T3 Cells. Protein Conformation. Sequence Homology, Amino Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878155.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Lmo2 protein, mouse; 0 / Metalloproteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


84. Bahammam AS, Basha SJ, Masood MI, Shaik SA: Outcome of patients with hematological malignancies admitted to the intensive care unit with life-threatening complications. Saudi Med J; 2005 Feb;26(2):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with hematological malignancies admitted to the intensive care unit with life-threatening complications.
  • OBJECTIVE: To assess the outcome of patients with hematological malignancies (HM) admitted to medical intensive care unit (MICU) and to identify prognostic factors that may affect patients' outcome.
  • Demographic, physiological, clinical, laboratory and therapeutic data were collected on admission to MICU.
  • RESULTS: Thirty-four percent of the patients had acute lymphocytic leukemia; 25% had acute myelocytic leukemia (AML) followed by non-Hodgkin's lymphoma in 20%, only 13.6% of these patients were in remission.
  • The reasons for admission of these patients into MICU were shock (34.15%), respiratory failure (31.8%), cardiac arrest (20.4%), neurological causes (9.1%) and for other causes like small bowel perforation, hepatic failure, acute renal failure and metabolic disorders (4.5%).
  • The overall in-hospital mortality was 72.7%, intensive care unit (ICU) mortality 61%, and the mean length of stay in the MICU was 5.4 +/- 4.8 days.
  • CONCLUSION: Although mortality in patients with HM requiring ICU care is high, our results indicate that critical care support may be lifesaving.
  • Apart from remission status and AML disease, no other prognostic factor could be identified.
  • [MeSH-minor] Adult. Comorbidity. Critical Care. Female. Hospital Mortality. Humans. Intensive Care Units. Leukemia, Myeloid, Acute / mortality. Male. Middle Aged. Prognosis. Prospective Studies. Retrospective Studies. Saudi Arabia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770299.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


85. Miao K, Li J, Qiu H, Zhang R, Chen L, Wu H, Wang R, Zhang J: The chromosomal translocation (11;14) (p13; q11) in acute B-Cell lymphocytic leukemia. Onkologie; 2010;33(7):385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chromosomal translocation (11;14) (p13; q11) in acute B-Cell lymphocytic leukemia.
  • BACKGROUND: Cytogenetic abnormalities are the most important independent prognostic factors of acute leukemia and imply the potential molecular mechanism of the disease.
  • Translocation (11;14)(p13;q11) has been predominantly found in T-cell acute lymphocytic leukemia (ALL) but is rare in B-cell ALL.
  • CASE REPORT: We present the case of a 30-year-old male patient, who presented with symptomatic anemia, thrombocytopenia and leukocytosis.
  • CONCLUSIONS: Translocation (11;14) (p13;q11) in B-cell ALL is rare, but it is worth exploring the molecular mechanisms and discovering the prognostic value in more B-cell ALL patients.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. Leukemia, B-Cell / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Chromosome Banding. Disease Progression. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Remission Induction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20631486.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


86. Cai Y, Xu Z, Xie J, Ham AJ, Koury MJ, Hiebert SW, Brandt SJ: Eto2/MTG16 and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription factor in murine erythroid progenitors. Biochem Biophys Res Commun; 2009 Dec 11;390(2):295-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TAL1 (or SCL) gene, originally discovered through its involvement by a chromosomal translocation in T-cell acute lymphoblastic leukemia, encodes a basic helix-loop-helix (bHLH) transcription factor essential for hematopoietic and vascular development.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6234-47 [18710942.001]
  • [Cites] Science. 2004 Aug 27;305(5688):1286-9 [15333839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5039-43 [2740341.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2248-59 [10688671.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6792-803 [11118214.001]
  • [Cites] Yeast. 2001 May;18(7):657-62 [11329175.001]
  • [Cites] Annu Rev Immunol. 2002;20:301-22 [11861605.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6703-12 [12242670.001]
  • [Cites] Gene. 2003 Jan 16;303:1-10 [12559562.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7585-99 [14560005.001]
  • [Cites] Eur J Haematol. 2003 Dec;71(6):439-47 [14703694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):10128-32 [2602361.001]
  • [Cites] EMBO J. 1990 Feb;9(2):415-24 [2303035.001]
  • [Cites] EMBO J. 1992 Nov;11(11):4073-81 [1396592.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1200-8 [8118024.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Blood. 1995 Jul 1;86(1):164-75 [7540882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7075-9 [7624372.001]
  • [Cites] Genetics. 1995 Jun;140(2):573-86 [7498738.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1777-86 [9292510.001]
  • [Cites] Protein Sci. 1998 Mar;7(3):706-19 [9541403.001]
  • [Cites] Blood. 1998 May 15;91(10):3756-65 [9573012.001]
  • [Cites] Genomics. 1998 Sep 15;52(3):332-41 [9790752.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4958-67 [10490830.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3106-16 [15265794.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9576-85 [16227606.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(23):10235-50 [16287841.001]
  • [Cites] EMBO J. 2006 Jan 25;25(2):357-66 [16407974.001]
  • [Cites] Biochem J. 2006 Oct 15;399(2):297-304 [16800816.001]
  • [Cites] Development. 2006 Dec;133(24):4913-23 [17108004.001]
  • [Cites] Genes Dev. 2007 Apr 15;21(8):942-55 [17437998.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • (PMID = 19799863.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL049118; United States / NHLBI NIH HHS / HL / HL049118-15; United States / NHLBI NIH HHS / HL / R01 HL49118; United States / NHLBI NIH HHS / HL / R01 HL049118-15; United States / NCI NIH HHS / CA / 5P30CA068485; United States / NCI NIH HHS / CA / P30 CA068485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CBFA2T2 myeloid-transforming gene-related protein; 0 / Cbfa2t3 protein, mouse; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Tal1 protein, mouse; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS151956; NLM/ PMC2774815
  •  go-up   go-down


87. Aleskog A, Norberg M, Nygren P, Rickardson L, Kanduri M, Tobin G, Aberg M, Gustafsson MG, Rosenquist R, Lindhagen E: Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination. Leuk Lymphoma; 2008 Dec;49(12):2333-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
  • We, here, evaluated the in vitro activity of rapamycin with regard to tumor-type specificity and possible mechanisms of drug resistance in 97 tumor cell samples from patients and in a resistance-based cell line panel, using the fluorometric microculture cytotoxicity assay.
  • Rapamycin was dose-dependently cytotoxic in patient tumor cells and in cell lines.
  • In primary cells, rapamycin was more active in hematological than in solid tumor samples, with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia being the most sensitive tumor types.
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Chlorambucil. Cisplatin. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Leukemia, Lymphocytic, Chronic, B-Cell. Taxoids. Tumor Cells, Cultured. Vincristine

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Dec;49(12):2235-6 [19052968.001]
  • (PMID = 19052982.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Taxoids; 15H5577CQD / docetaxel; 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


88. Simon T, Kohlhase J, Wilhelm C, Kochanek M, De Carolis B, Berthold F: Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A; 2010 Jun;152A(6):1575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECQL4 mutations cause genetic instability and increase the risk of malignant disease.
  • He subsequently developed large cell anaplastic T cell lymphoma at the age of 9 years, diffuse large cell B lymphoma and osteosarcoma when he was 14 years old, and finally acute lymphatic leukemia when he was 21 years old.
  • The most remarkable clinical features are young age, spontaneous remission of diffuse large cell lymphoma, and severe CNS and skin toxicity of cytotoxic treatment.
  • [MeSH-major] Bone Neoplasms / genetics. Leukemia, Large Granular Lymphocytic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Osteosarcoma / genetics. RecQ Helicases / genetics. Rothmund-Thomson Syndrome / genetics


89. Burns CA, Scott GA, Miller CC: Leukemia cutis at the site of trauma in a patient with Burkitt leukemia. Cutis; 2005 Jan;75(1):54-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis at the site of trauma in a patient with Burkitt leukemia.
  • Leukemia cutis is an infrequent finding in patients with acute lymphocytic leukemia (ALL).
  • We present a patient with Burkitt ALL (L3ALL) who developed leukemia cutis at the site of trauma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Leukemia / pathology. Scalp / injuries. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732436.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Inoue T, Sato T, Okada H, Kayano H, Watanabe Y, Kikuta T, Tsuda M, Sueyoshi K, Takenaka T, Suzuki H: Granulomatous interstitial nephritis in chronic lymphocytic leukaemia. Nephrol Dial Transplant; 2010 Dec;25(12):4107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous interstitial nephritis in chronic lymphocytic leukaemia.
  • We present a case of granulomatous interstitial nephritis (GIN) associated with chronic lymphocytic leukaemia (CLL).
  • GIN is a rare pathological finding noted in renal biopsy specimens.
  • In this case, acute renal injury probably resulted from GIN, and urgent dialysis was required, despite sufficient chemotherapy.
  • Immunohistochemical analyses of a biopsy specimen revealed invasion of CD20( +) CLL cells, surrounded by reactive T cells, and granuloma formation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Nephritis, Interstitial / diagnosis. Nephritis, Interstitial / etiology
  • [MeSH-minor] Acute Kidney Injury / etiology. Acute Kidney Injury / therapy. Antigens, CD3 / metabolism. Antigens, CD5 / metabolism. Cell Movement. Humans. Male. Middle Aged. Renal Dialysis. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702535.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD5
  •  go-up   go-down


91. Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E: Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther; 2009 Feb;9(2):207-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The introduction of mAbs has changed the clinical approach to patients with lymphoma and leukemia.
  • RESULTS: Rituximab (anti-CD20) was the first mAb developed for the treatment of B-cell lymphomas.
  • Several randomized studies have demonstrated its efficacy in lymphomas and low toxicity profile; rituximab also has significant activity in chronic lymphocytic leukemia (CLL).
  • Alemtuzumab (anti-CD52) has shown efficacy in previously untreated or refractory CLL patients, while gemtuzumab ozogamicin (anti-CD33) appears to have significant activity in acute myeloid leukemias and myelodysplastic syndromes.
  • CONCLUSIONS: In the next few years, investigations will be concentrated on the improvement of the older mAbs, and the development of new mAbs, targeting molecules important for malignant cell cycle and survival in an attempt to further improve patient survival.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236251.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 107
  •  go-up   go-down


92. Wilson F, Tefferi A: Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review. Leuk Lymphoma; 2005 Jul;46(7):1045-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review.
  • Acute lymphocytic leukemia (ALL) associated with eosinophilia is a rare occurrence, but a distinct clinicopathological entity.
  • [MeSH-major] Burkitt Lymphoma / complications. Eosinophilia / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019556.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  • [Number-of-references] 18
  •  go-up   go-down


93. Li S, Mann KP, Holden JT: Composite small lymphocytic lymphoma and extra-medullary myeloid tumor: a potential diagnostic pitfall. Int J Clin Exp Pathol; 2008;1(1):91-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite small lymphocytic lymphoma and extra-medullary myeloid tumor: a potential diagnostic pitfall.
  • Reported herein is a case of composite small lymphocytic lymphoma (SLL) and extramedullary myeloid tumor (EMT) occurring in the same lymph node.
  • Routine morphologic examination revealed a diffuse proliferation of small mature lymphocytes with numerous irregularly dispersed nodules, closely resembling SLL with prominent proliferation centers or Richter's transformation.
  • Flow cytometric immunophenotyping and immunohistochemical stains demonstrated the presence of SLL cells as well as myeloblasts, confirming the diagnosis of a composite SLL and EMT.
  • Conventional cytogenetics and fluorescence in situ hybridization studies revealed inversion 16 chromosome involving the core binding factor beta and myosin heavy chain 11 genes, characteristic of acute myeloid leukemia with abnormal bone marrow eosinophils and inv(16) or t(16;16) [CBFbeta/MYH11].

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2343-51 [16710033.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):250-6 [16616072.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):683-90 [16524977.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):445-52 [16191514.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):205-12 [12579990.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):957-68 [12213724.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):624-9 [11979092.001]
  • [Cites] Arch Pathol Lab Med. 1995 Sep;119(9):790-8 [7668936.001]
  • (PMID = 18784827.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480536
  • [Keywords] NOTNLM ; Extramedullary myeloid tumor / flow cytometric immunophenotyping / fluorescence in situ hybridization / immunohistochemistry / karyotype / small lymphocytic lymphoma
  •  go-up   go-down


94. Yan WH: HLA-G expression in hematologic malignancies. Expert Rev Hematol; 2010 Feb;3(1):67-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the context of hematologic malignancies, such as acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma, the expression and clinical significance of HLA-G was discussed; however, interpretation remains controversial.
  • In this review, we summarize HLA-G expression in hematologic malignancies and emphasize the clinical relevance of this expression to disease progression.
  • [MeSH-minor] HLA-G Antigens. Humans. Leukemia, Lymphoid / metabolism. Leukemia, Myeloid / metabolism. Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082935.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


95. Ashok L, Sujatha GP, Hema G: Estimation of salivary amylase and total proteins in leukemia patients and its correlation with clinical feature and radiographic finding. Indian J Dent Res; 2010 Oct-Dec;21(4):486-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of salivary amylase and total proteins in leukemia patients and its correlation with clinical feature and radiographic finding.
  • BACKGROUND: Leukemia is a fatal disease.
  • The oral manifestations of the leukemias occur early in the course of the disease and these oral features can at times act as a diagnostic indicator.
  • MATERIALS AND METHODS: In our study, samples of unstimulated saliva of 30 leukemia patients who were not on chemotherapy were collected and analyzed for salivary amylase and total protein.
  • [MeSH-major] Amylases / analysis. Jaw Diseases / radiography. Leukemia / metabolism. Saliva / enzymology. Salivary Proteins and Peptides / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alveolar Bone Loss / etiology. Alveolar Bone Loss / radiography. Case-Control Studies. Child. Child, Preschool. Ecchymosis / etiology. Female. Gingival Hypertrophy / etiology. Gingivitis / etiology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / metabolism. Male. Middle Aged. Mouth Diseases / etiology. Periapical Abscess / etiology. Periapical Abscess / radiography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Purpura / etiology. Radiography, Panoramic. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187610.001).
  • [ISSN] 1998-3603
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Salivary Proteins and Peptides; EC 3.2.1.- / Amylases
  •  go-up   go-down


96. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
  • Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
  • Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.
  • [MeSH-major] Neoplasms / surgery. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


97. Rolny C, Lu L, Agren N, Nilsson I, Roe C, Webb GC, Welsh M: Shb promotes blood vessel formation in embryoid bodies by augmenting vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor-beta signaling. Exp Cell Res; 2005 Aug 15;308(2):381-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This response may be the consequence of an increased number of VEGFR-2 positive cells at an early stage of EB development, a finding corroborated by both immunostaining and real-time RT-PCR.
  • The findings suggest that Shb may play a crucial role during early ES cell differentiation to vascular structures by transducing VEGFR-2 and PDGFR-beta signals.
  • [MeSH-minor] Animals. Antigens, CD31 / metabolism. Basic Helix-Loop-Helix Transcription Factors. Cell Differentiation / physiology. Cell Line. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Embryo Culture Techniques. Endothelial Cells / cytology. Endothelial Cells / metabolism. Gene Expression Profiling. Gene Expression Regulation, Developmental / physiology. Mice. Mutation / genetics. Oligonucleotide Array Sequence Analysis. Phenotype. Platelet Membrane Glycoprotein IIb / genetics. Platelet Membrane Glycoprotein IIb / metabolism. RNA, Messenger / metabolism. Signal Transduction / physiology. Transcription Factors / genetics. Transcription Factors / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15919073.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Platelet Membrane Glycoprotein IIb; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Shb protein, mouse; 0 / Tal1 protein, mouse; 0 / Transcription Factors; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


98. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • A quantitative PCR assay for ZAP-70 expression was established and ZAP-70 expression in a range of human B cell lines was compared with expression in the Jurkat T cell line.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was not detected in mature B cell lines but was detected in pre-B cell lines at a level comparable to that seen in T cells.
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adolescent. Blotting, Western. Bone Marrow Cells / metabolism. Cell Line, Transformed. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression. Humans. Jurkat Cells. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


99. Harrison TM, McKnight CA, Sikarskie JG, Kitchell BE, Garner MM, Raymond JT, Fitzgerald SD, Valli VE, Agnew D, Kiupel M: Malignant lymphoma in african lions (panthera leo). Vet Pathol; 2010 Sep;47(5):952-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemically, 10 of the 11 lions had T-cell lymphomas (CD3(+), CD79a(-)), and 1 lion was diagnosed with a B-cell lymphoma (CD3(-), CD79a(+)).
  • The spleen appeared to be the primary site of neoplastic growth in all T-cell lymphomas, with involvement of the liver (6/11) and regional lymph nodes (5/11) also commonly observed.
  • The B-cell lymphoma affected the peripheral lymph nodes, liver, and spleen.
  • According to the current veterinary and human World Health Organization classification of hematopoietic neoplasms, T-cell lymphoma subtypes included peripheral T-cell lymphoma (4/11), precursor (acute) T-cell lymphoblastic lymphoma/leukemia (2/11), chronic T-cell lymphocytic lymphoma/leukemia (3/11), and T-zone lymphoma (1/11).
  • The single B-cell lymphoma subtype was consistent with diffuse large B-cell lymphoma.
  • Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing by immunohistochemistry on sections of malignant lymphoma was negative for all 11 lions.
  • In contrast to domestic and exotic cats, in which B-cell lymphomas are more common than T-cell lymphomas, African lions in this study had malignant lymphomas that were primarily of T-cell origin.
  • [MeSH-major] Lions. Lymphoma / veterinary. Lymphoma, B-Cell / veterinary. Lymphoma, T-Cell / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610770.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Diamantidis MD, Ioannidou-Papagiannaki E, Kountouras J, Mandala E, Tsapournas G, Frida-Michailidou I, Klonizakis P, Zavos C, Haralambidou-Vranitsa S, Vlachaki E, Parapanisiou E, Klonizakis I: High prevalence of Helicobacter pylori infection in Greek patients with myelodysplastic syndromes. Acta Haematol; 2010;124(3):141-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in 20 cases, significant variation in the PB lymphocytic proportion possibly attributable to Hp-I was ascertained, in contrast to the expected MDS ratio.
  • CONCLUSION: Although there is no evidence for a causal relationship between Hp-I and MDS, the increased prevalence of Hp-I among the MDS patients is an interesting finding that deserves further investigation as it may indicate a common factor causing susceptibilities to both MDS and Hp-I or that Hp might influence the pathophysiology of MDS.
  • [MeSH-minor] Aged. Antigens, CD / blood. Case-Control Studies. Causality. Cohort Studies. Female. Greece / epidemiology. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / immunology. Lymphocytes / immunology. Male. Middle Aged






Advertisement